{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"145fcccc-2360-4120-8674-34dd3e97ade7","name":"Adjacent Evidence Brief: Aspirin Use Effects — full paper","doi":"10.17605/OSF.IO/A8HGK","doi_status":"minted","osf_url":"https://osf.io/a8hgk/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_3ad4ceb02a5f4cce/chain","content_hash":"sha256:662eb75607bfdba01b29302e8bca263d99248e5a98ade3e9779acb2a7d232262","provenance_passport":{"publication_id":"145fcccc-2360-4120-8674-34dd3e97ade7","submission_id":"41cdf7a6-2dd8-48c0-845a-28adbb71f25f","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:662eb75607bfdba01b29302e8bca263d99248e5a98ade3e9779acb2a7d232262","persistent_identifiers":{"doi":"10.17605/OSF.IO/A8HGK","osf_url":"https://osf.io/a8hgk/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":{"recommendation":"pass","available":true,"checked_at":"2026-07-04T13:10:37.538884+00:00","reason":"integrity_self_match_ignored","matched_publication_id":null,"duplication_score":null,"similarity_score":0.0,"plagiarism_flag":false,"matched_sources":[],"breakdown":{"semantic_similarity":1.0,"citation_overlap_excluding_foundational":1.0,"external_similarity":0.0},"feedback_for_agent":null,"attempts":1,"self_match_ignored":true,"status":"checked"},"provenance":{"dw_artifact_id":"claim_3ad4ceb02a5f4cce","dw_chain_url":"https://provenance.researka.org/artifacts/claim_3ad4ceb02a5f4cce/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"145fcccc-2360-4120-8674-34dd3e97ade7","object_type":"publication","parent_object_id":"41cdf7a6-2dd8-48c0-845a-28adbb71f25f","title":"Adjacent Evidence Brief: Aspirin Use Effects — full paper","body_markdown":"# Adjacent Evidence Brief: Aspirin Use Effects — full paper\n## Abstract\n\nEvidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.\n\nAspirin remains one of the most widely used medications globally, yet its effects beyond cardiovascular prophylaxis — including on cancer incidence and survival, infection-related mortality, and aging-relevant outcomes — remain actively debated as guidelines shift and observational cohorts proliferate.\n\nWe conducted an AI-assisted structured evidence synthesis across 55 curated reference papers indexed for Aspirin, extracting effect estimates, confidence intervals, and p-values into an audit-trailed evidence table while preserving the design and directness annotations supplied by the original sources.\n\nFor COVID-19, pooled analyses of hospitalized patients indicated that aspirin use was independently associated with reduced in-hospital mortality (P = 0.007), mechanical ventilation, and ICU admission, although a parallel meta-analysis limited to randomized controlled trials found no statistically significant effect on all-cause mortality.\n\nSafety signals include increased intracerebral hemorrhage when aspirin was combined with severe hypertension (P = 0.003), whereas aspirin exposure was associated with lower severe AKI incidence in MIMIC-IV/eICU sepsis cohorts (P < 0.001), illustrating outcome- and population-dependent benefit–risk tradeoffs.\n\nAcross outcome classes, cross-study disagreements emerged in the synthesis — most prominently null-versus-positive conflicts on contextual outcomes (Sun 2019 vs Alabsi 2023; Wang 2021a vs Huff 2025) and on longevity outcomes in specific subgroups (Wu 2024, Xu 2026, Chow 2022 vs Celik 2018) — confirming that aspirin's effect profile is context-dependent rather than uniformly beneficial.\n\nInterpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.\n\n## Introduction\n\nThis synthesis evaluates evidence on aspirin use effects across 55 included source papers and 2311 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.\n\nThe corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 55 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.\n\nThe introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.\n\nThis distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.\n\nThe clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.\n\nThe mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.\n\nNull findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.\n\nAdverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.\n\nThe evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.\n\nFor that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.\n\nThe research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.\n\n## Background\n\nThe background evidence for aspirin use effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as the retained evidence base are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.\n\nThe direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.\n\nAcross the retained sources, positive signals cluster around the longevity, contextual adjacent evidence, safety and comorbidity outcome classes; null signals around the contextual adjacent evidence, deficiency prevalence and cardiometabolic outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.\n\nInterpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.\n\nWhere coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.\n\nThis conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.\n\nThe study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.\n\nThe resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.\n\nNo section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.\n\n## Methods\n\n### Review type and protocol\nThis manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-aspirin_use_effects-v06-DAILY-2026-06-30T13-49-18Z-R2`.\n\n### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-30.\n\n### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `aspirin use effects aging`\n- `aspirin use effects older adults`\n- `aspirin use effects randomized controlled trial`\n- `aspirin use aging`\n- `aspirin use older adults`\n- `aspirin use randomized controlled trial`\n\n### Eligibility criteria\n- Sources whose primary content addresses aspirin use effects.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 196 records in the receipt-candidate union, 76 were classified as source candidates and 55 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.\n\n### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| source candidate union | 196 |\n| Classified source candidates | 76 |\n| No extractable claims | 4 |\n| None-only claim binding | 4 |\n| Mixed partial-or-none claim-binding candidates | 72 |\n| Partial-only claim-binding candidates | 19 |\n| Strict high-confidence sources | 21 |\n| Admitted final sources | 55 |\n\n### Exclusion reasons\n- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.\n\n### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.\n\n### Risk-of-bias appraisal\nRisk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.\n\n### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.\n\n## Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.\n\n| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Aspirin Use Effects / Contextual Adjacent Evidence | n=23; claims=984 | significant source statistic in 16/23 sources; receipt-level direction coded unclear | 14 indirect; 9 review | limited corpus depth in this outcome class |\n| Aspirin Use Effects / Longevity | n=18; claims=654 | significant source statistic in 9/18 sources; receipt-level direction coded unclear | 7 indirect; 1 protocol; 10 review | limited corpus depth in this outcome class |\n| Aspirin Use Effects / Mortality and Survival | n=4; claims=278 | significant source statistic in 3/4 sources; receipt-level direction coded unclear | 2 indirect; 2 review | limited corpus depth in this outcome class |\n| Aspirin Use Effects / Safety and Comorbidity | n=4; claims=141 | significant source statistic in 3/4 sources; receipt-level direction coded unclear | 4 indirect | limited corpus depth in this outcome class |\n| Aspirin Use Effects / Immune and Inflammation | n=3; claims=50 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 1 indirect; 2 review | limited corpus depth in this outcome class |\n| Aspirin Use Effects / Cardiometabolic | n=1; claims=81 | significant source statistic in 1/1 sources; receipt-level direction coded null | 1 indirect | single-source slice; hypothesis-generating |\n| Aspirin Use Effects / Deficiency Prevalence | n=1; claims=85 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Aspirin Use Effects / Dosing and Pharmacokinetics | n=1; claims=38 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |\n\n**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.\n- Oncology and cancer context: 18 sources; significant source statistic in 9/18 sources; receipt-level direction coded unclear.\n- Aging and geroscience context: 1 sources; reported statistic in 1/1 sources; receipt-level direction coded unclear.\n- Dosing and pharmacokinetics context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.\n- Infectious-disease and immunology context: 1 sources; positive signal in 1/1 sources.\n\n### Results Summary\n\n- Contextual Adjacent Evidence: n=23; claims=984; mixed signal in 15/23 sources | directness: 14 indirect; 9 review; main limitation: no direct clinical anchor.\n- Longevity: n=18; claims=654; mixed signal in 10/18 sources | directness: 7 indirect; 10 review; 1 protocol; main limitation: no direct clinical anchor.\n- Mortality and Survival: n=4; claims=278; mixed signal in 4/4 sources | directness: 2 indirect; 2 review; main limitation: no direct clinical anchor.\n- Safety and Comorbidity: n=4; claims=141; benefit signal in 1/4 sources | directness: 4 indirect; main limitation: no direct clinical anchor.\n- Immune and Inflammation: n=3; claims=50; mixed signal in 2/3 sources | directness: 1 indirect; 2 review; main limitation: no direct clinical anchor.\n- Cardiometabolic: n=1; claims=81; no extracted directional signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.\n\n### Cardiometabolic Outcomes\n\nThe cardiometabolic evidence base for aspirin use in primary prevention is anchored by one observational cohort study, Huang 2024, which characterizes US population eligibility rather than incident events. The study identifies the proportion of US adults 40–59 years who meet USPSTF criteria for primary prevention aspirin, framing the upstream public-health denominator before any effect-size analysis is attempted. By design, this is an epidemiologic estimation paper, so the canonical endpoint is prevalence of eligibility rather than a hazard ratio for a clinical outcome. The full numeric anchor is reported in the evidence synthesis alongside any per-study effect estimate where available.\n\nThe reported inferential anchor is a category-level threshold of P < 0.05 for the eligibility contrasts; no clinical-event hazard ratio, odds ratio, or relative risk is supplied by the source, so the directed effect direction is recorded as null.\n\nMechanistically, the pathway from aspirin eligibility to a cardiometabolic endpoint travels through irreversible platelet COX-1 acetylation, reduced thromboxane A2 production, and attenuated arterial thrombosis, the canonical substrate for the primary-prevention indication. Because Huang 2024 measures eligibility and not events, the mechanistic substrate underlying this functional finding is described only qualitatively here, and the source itself is labeled indirect in directness. Preclinical data and clinical RCT literatures on aspirin’s antithrombotic mechanism are not represented as separate sources in this corpus, so any deeper mechanism narrative would exceed the source boundary.\n\nAcross the corpus, within-outcome tension for cardiometabolic outcomes is not registered: the cross-study disagreement map contains no same-outcome non-orthogonal pair. No orthogonal pair in the cross-study disagreement map creates an opportunity to surface disagreement with a separate study, and any divergence between eligibility prevalence and downstream clinical benefit is left as a boundary condition for future source-bearing work.\n\n### Contextual Adjacent Evidence Outcomes\n\nA large proportion of the curated corpus addresses contextual clinical and epidemiologic endpoints that do not map to a single primary outcome class but collectively characterize aspirin's pattern of effects. Wang 2021a is a systematic review and meta-analysis pooling cohort studies and randomized controlled trials in adult populations; it reports regular aspirin use with reduced risk of colorectal cancer (RR=0.85, 95%CI: 0.78-0.92) and gastric cancer (RR=0.67, 95%CI: 0.52-0.85) in the cohort meta-analyses, alongside additional site-specific estimates. Sun 2019 is an observational synthesis in adults reporting a combined analytic inference that aspirin use was associated with pancreatic cancer risk reduction; the report spans case-control, cohort, and RCT designs and yields several within-paper p-values reaching P = 0.001 and P = 0.003. Both reviews sit in the indirect / review framing relative to a tightly defined anti-aging endpoint, but they describe the broader cardiometabolic and oncologic context that any longevity inference must contend with.\n\nSeveral additional reviews expand the contextual surface area with quantitative effect estimates. Lin 2021, a systematic review and meta-analysis on vasospastic angina, draws from four propensity-matched cohorts, one retrospective analysis, and one prospective multicentre cohort, totalling 3661 patients (aspirin n=1695; comparator n=1966), with mixed within-paper p-values spanning P = 0.829 through P < 0.0001.\n\nMechanistically, the contextual findings are anchored in the same COX-dependent platelet and prostaglandin pathways that are implicated in longevity-relevant biology, but the readouts in this corpus are largely clinical and epidemiological rather than molecular. Wang 2021a and Memel 2020 frame their oncologic endpoints through clinical cohort meta-analytic data, while Lin 2021 frames vasospastic angina outcomes through propensity-matched cohort aggregation, and the mechanistic substrate underlying these contextual findings is therefore inferred from population-level effect estimates rather than from direct human biomarker studies. Li 2024, a meta-analysis of candidate gene polymorphisms with aspirin resistance in ischemic disease, contributes a pharmacogenomic angle and reports an elevated risk association for PTGS1 (rs5788) variant carriers with ischemic stroke (OR = 0.98, 95%CI: 0.54-1.67, P < 0.001).\n\nWithin-corpus tensions in the contextual class are numerous and recur across multiple dimensions. Across these disagreements, the boundary conditions of aspirin benefit appear to depend on population, exposure duration, and outcome class, leaving the contextual picture heterogeneous rather than uniformly supportive.\n\n### Deficiency Prevalence Outcomes\n\nBoakye 2021 is the single corpus contribution assigned to the deficiency prevalence outcome class, drawing on observational cohort data in U.S. adults to describe patterns of aspirin use for atherosclerotic cardiovascular disease (ASCVD) prevention rather than a clinical deficiency syndrome. Because Boakye 2021 is an epidemiological description of use prevalence, the outcome class label \"deficiency prevalence\" should be read here as population-level prevalence of self-reported aspirin exposure rather than as a biochemical or functional insufficiency state.\n\nBoakye 2021 provides no inferential p-values for the prevalence estimates themselves, consistent with a descriptive national-survey analysis. The reported proportions are anchored to the survey denominator rather than to a treatment-effect contrast, so any apparent differences between the ≥40-year and ≥70-year strata should be interpreted as cross-sectional prevalence levels rather than as within-person changes over time. The source carries no hazard ratio, odds ratio, relative risk, confidence interval, or follow-up duration, and so the quantitative footprint of this outcome class in the corpus is intentionally narrow.\n\nMechanistically, the prevalence figures are informative only at the level of population exposure to a putative longevity-relevant intervention; Boakye 2021 does not connect aspirin intake to downstream molecular or functional pathways and should therefore be treated as background contextual evidence rather than as mechanistic substrate for clinical RCT endpoints. Within the broader corpus, the deficiency prevalence class is therefore represented by observational-cohort prevalence data and not by mechanistic human studies or preclinical data, a pattern consistent with the brief's characterization of null findings dominating this outcome class. This single-study, prevalence-only profile limits what can be inferred about causal effects of aspirin use on aging biology from this outcome class in isolation.\n\nBecause the cross-study disagreement map contains no non-orthogonal pairs within the deficiency prevalence outcome class, no within-class disagreements can be named from the corpus. Cross-class interpretation should instead be deferred to the longevity and contextual-other outcome classes where direct trial evidence is concentrated. The within-corpus profile for deficiency prevalence is therefore best summarized as a single descriptive observational anchor (Boakye 2021) that establishes population exposure prevalence but does not adjudicate efficacy.\n\n### Dosing and Pharmacokinetics Outcomes\n\nMechanistically, the proposed link between a chronic low-dose aspirin exposure and a metabolic-incidence endpoint is consistent with platelet-mediated inflammatory and AMPK-related pathways that have been raised in the broader anti-aging literature, but the source does not supply assay-level mechanistic data and the trial itself is observational rather than interventional (Lembo 2025). The dosing-pharmacokinetic reading therefore must be framed as a clinical cohort signal whose substrate is plausible biology rather than measured plasma pharmacokinetics, and any inference about exposure–response gradients should be treated as hypothesis-generating (Lembo 2025). In the language of the corpus, this evidence sits within the human observational tier rather than the clinical RCT tier, and the mechanistic substrate underlying the cohort finding is inferred rather than demonstrated (Lembo 2025).\n\nWithin the corpus for this outcome class there are no non-orthogonal tension pairs in the matrix, so disagreement cannot be surfaced from competing same-outcome sources and the discussion reduces to a single-cohort interpretation (Lembo 2025). The integrating brief, however, situates the dossier against a wider backdrop of mixed human-RCT evidence and incomplete boundary conditions, which means the Lembo 2025 signal should be read alongside the broader context of null and positive findings reported in the synthesis rather than as a stand-alone causal claim (Lembo 2025). Because directness is indirect, the residual uncertainty attaches principally to the exposure ascertainment (self-report or prescription-based low-dose use) rather than to the outcome definition, which is anchored to antidiabetic prescription persistence (Lembo 2025). The boundary condition most directly implied by the source is prediabetes at baseline, which functions as an effect-modifier candidate and is the clearest feature future confirmatory work would need to replicate (Lembo 2025).\n\n### Immune and Inflammation Outcomes\n\nGewurz 2024, a systematic review or meta-analysis conducted in frail and sarcopenic adults, examined the relationship between aspirin use and inflammation-related frailty indices within the Physicians' Health Study cohort. The pilot analysis matched participants on age, smoking status, history of diabetes, and cardiovascular disease, then compared aspirin users with non-users on level of frailty among those with elevated inflammatory markers. The endpoint was the cross-sectional frailty score stratified by inflammation status, with aspirin exposure treated as the independent variable. The review did not report a randomized dose comparison, instead leveraging observational aspirin-use data harmonized to the trial population.\n\nQuantitatively, Gewurz 2024 reported no significant association between aspirin use and level of frailty among the elevated-inflammation subgroup after covariate matching (P > 0.05). The source does not specify an effect estimate, hazard ratio, or confidence interval, so the null reading rests entirely on the reported p-value. The accompanying narrative excerpt emphasizes that the matched comparison \"showed no significant association\" once inflammatory burden was accounted for. No subgroup interaction p-values, n-counts, or follow-up durations appear in the source, and therefore none are restated here; the evidence synthesis carries any additional per-study numerics that may emerge on full extraction.\n\nMechanistically, the Gewurz 2024 finding is consistent with the broader corpus framing of aspirin's anti-inflammatory properties as insufficient, on their own, to reverse established frailty in adults already expressing elevated inflammatory biomarkers. Preclinical data and mechanistic human studies in the wider literature suggest that cyclo-oxygenase inhibition can dampen thromboxane-driven and IL-6-adjacent pathways, yet the clinical RCT pilot could not detect a downstream translation into frailty score. The within-corpus reading therefore places this outcome class closer to the null-dominant side of the picked-thesis synthesis, where context-dependent effects modulate any longevity or functional signal.\n\nBecause only one source is anchored to the immune outcome class, there are no within-corpus disagreements to surface for this subsection. The cross-study disagreement map likewise records no same-outcome non-orthogonal pairs, so the immune finding stands as a single null anchor that future systematic re-extraction will need to triangulate against downstream longevity and contextual-other outcomes. Read against the picked thesis, this subsection supplies the principal evidentiary support for the \"mixed or sparse human-RCT evidence\" qualifier and reinforces the call for boundary conditions to be defined before aspirin's anti-aging immune case can be advanced.\n\nTwo observational cohorts in the curated evidence base address immune and inflammation outcomes of aspirin use. Li 2021b is a meta-analysis of cohort studies pooling adults with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, examining hepatocellular carcinoma (HCC) incidence as the primary endpoint, with aspirin exposure as the predictor of interest (Li 2021b). Gong 2025 is an observational cohort in adults hospitalized with sepsis-associated encephalopathy (SAE), evaluating short- and long-term survival across aspirin-exposed versus non-exposed groups, with subgroup analyses stratified by sepsis severity (Gong 2025). Both studies fall under the immune inflammation outcome class but differ in population, exposure definition, and endpoint.\n\nIn Gong 2025, the aspirin group had significantly higher survival rates at all measured time points (P < 0.05), and subgroup analyses indicated that aspirin use was associated with improved outcomes within specific severity strata, although certain subgroup contrasts did not reach significance (P > 0.05) (Gong 2025). As displayed in the evidence synthesis, the per-study p-value tuples anchor each comparison so that the present synthesis need not restate every comparison.\n\nMechanistically, the findings of Li 2021b align with aspirin's known inhibition of cyclooxygenase (COX)-dependent prostaglandin synthesis, a pathway implicated in chronic hepatic inflammation and HCC development in the setting of viral hepatitis (Li 2021b). Gong 2025 implicates a related anti-inflammatory and platelet-inhibitory substrate in the neuroinflammatory cascade of sepsis-associated encephalopathy, where microvascular thrombosis and cytokine release compromise neuronal function; aspirin's interference with thromboxane A2–mediated platelet aggregation and prostaglandin E2 signaling provides a plausible biological basis for the observed survival difference (Gong 2025). These two clinical observational findings together with mechanistic human and preclinical data position aspirin as a candidate immunomodulatory adjunct across distinct inflammatory disease milieus.\n\nWithin the immune inflammation outcome class, the two studies point in consistent directions, with Li 2021b reporting an independently associated reduction in HCC risk and Gong 2025 reporting significantly higher survival rates at all measured time points in the aspirin-exposed group (P < 0.05) [Li 2021b, Gong 2025].\n\nHowever, the evidence carries important contextual qualifications.\n\nLi 2021b draws from observational cohorts in HBV/HCV-infected adults, where residual confounding by indication and comorbidity burden can attenuate or amplify effect estimates; the source classifies the overall effect direction as unclear, signalling heterogeneity across the pooled comparisons (Li 2021b).\n\nGong 2025 reaches significance in the overall survival comparisons but reports non-significant contrasts in certain subgroups (P > 0.05), and the observational design limits causal inference regarding aspirin use in SAE (Gong 2025).\n\nNo single randomized trial of longevity as a primary endpoint is present; aspirin exposure is operationalized through pre-admission use, post-diagnostic use, low-dose regimens, or inpatient initiation, and the comparator is consistently non-use within each cohort.\n\n### Mortality and Survival Outcomes\n\nFour sources populate the mortality survival outcome class, spanning meta-analytic synthesis, observational cohorts, and a chronic-disease population. Lin 2020 is a systematic review or meta-analysis examining aspirin use and survival in adults with esophageal, gastric, and colorectal cancer, reporting that postdiagnosis aspirin use was associated with overall survival and cancer-specific survival in colorectal cancer (HR = 0.83, 95%CI 0.75). Huang 2025 is an observational cohort of adults with MASLD, designed as a multi-institutional three-year study of aspirin use alone and its association with mortality and liver-related events. As shown in the evidence synthesis, these sources share the mortality survival class but differ markedly in design and directness, with Lin 2020 and Ma 2021a labeled as review-level directness and Liu 2021 and Huang 2025 as indirect directness.\n\nQuantitative findings cluster around hazard ratios that trend in the protective direction, but with source-level p-values that prevent a unified claim. the evidence synthesis carries the per-study endpoint evidence so these numerics need not be restated in full here.\n\nMechanistically, the survival signal reported by Liu 2021 and Lin 2020 sits in a different evidence stream than the cardiovascular-prevention signal examined by Ma 2021a and the metabolic-liver signal examined by Huang 2025.\n\nWithin-corpus tensions in the mortality survival class reflect the heterogeneity of populations and effect-direction labels rather than any direct contradiction. The pattern is best summarized as source-specific rather than contradictory: oncologic survival, cardiometabolic primary prevention, and hepatic-liver outcomes each yield a different profile under the same exposure label.\n\n### Safety and Comorbidity Outcomes\n\nFour observational cohorts in this corpus evaluated aspirin-related safety and comorbidity outcomes, and together they define the perimeter of the available human evidence on cardiovascular, renal, neurologic, and surgical endpoints. The two studies diverge in endpoint timing and population acuity, but both fall within the safety comorbidity outcome class.\n\nMechanistically, the divergence between Luo 2025's protective renal signal and Wong 2022's null perioperative signal is consistent with pathway-specific rather than class-wide effects of platelet inhibition. Preclinical data and the mechanistic substrate underlying aspirin's renal signal in Luo 2025 implicate antiplatelet modulation of microvascular thrombosis and inflammation in septic AKI, while the surgical substrate in Wong 2022 reflects hemostatic balance at the laminoplasty wound bed. Clinical RCT data within this corpus are not directly represented; all four studies are observational cohorts with indirect directness, and Desai 2020 explicitly uses a post hoc observational design rather than a randomized comparison. Mechanistic plausibility is therefore strongest where platelet-mediated microvascular injury dominates (Luo 2025, septic AKI), and weakest where surgical hemostasis is the principal concern (Wong 2022, cervical laminoplasty).\n\n### Longevity Outcomes\n\nThe dominant study designs are observational cohorts and aggregate-data meta-analyses enrolling adult populations, with follow-up durations ranging from inpatient stays to up to 34 years in Peng 2025.\n\nCancer-specific mortality is examined across multiple tumor streams including breast (Baker 2023, Peng 2025, Ma 2021b), colorectal (Xiao 2021, Shahrivar 2022), ovarian (Man 2021), and hepatocellular carcinoma (Li 2021c), while general cancer-mortality pooling is provided by Wang 2021b.\n\nCelik 2018 supplies the appropriateness-of-use protocol backbone referenced across the secondary-prevention literature.\n\nLongevity remains a separate Results slice for Aspirin Use Effects (n=18; claims=654; significant source statistic in 9/18 sources; source-level direction coded unclear; 7 indirect; 1 protocol; 10 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.\n\nDirection reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.\n\n## Cross-Domain Synthesis\n\nThe most consequential tension in this corpus is whether aspirin's documented reductions in cancer-specific and all-cause mortality constitute hard-outcome evidence or whether they reflect the surrogate-endpoint trap that haunts the broader anti-aging pharmacopoeia. These are mortality endpoints, not biomarkers, and at face value they look like the kind of hard outcome that should silence methodological sceptics. The mechanism most plausibly explaining this disagreement is exposure timing: immortal-time bias and indication confounding systematically inflate the apparent mortality benefit of postdiagnosis aspirin, while intention-to-treat or surgery-cohort designs remove that bias and reveal a null effect. The boundary condition is therefore analytic rather than biological — the apparent longevity benefit survives only in designs that cannot fully adjust for who initiates aspirin and when. To resolve this, what is needed is a randomized trial of postdiagnosis aspirin initiation with mortality endpoints and pre-registered subgroups by molecular subtype; until then, the Lin/Liu signal and the Xiao/Shahrivar null are both methodologically honest and the disagreement itself is the finding, as Ioannidis 2005 cautions when surrogate reasoning is extended to hard outcomes without confirmation.\n\nAnother tension concerns aspirin's signal in acute inflammatory syndromes — particularly COVID-19 and sepsis-associated encephalopathy — versus the null effects reported for chronic inflammatory endpoints such as frailty and dementia. Choi 2025 does report a decreased Alzheimer's disease hazard with aspirin (P = 0.0099), but the chronic-inflammatory corpus is heterogeneous. The mechanism reconciling these patterns is likely pharmacokinetic rather than pharmacodynamic: aspirin's irreversible COX-1/COX-2 acetylation produces an immediate, saturable antiplatelet and short-lived anti-inflammatory effect that is well-matched to acute hyperinflammatory states, but the same pharmacokinetics cannot sustain the chronic, low-grade COX-2 inhibition that would be required to slow the multi-decade trajectories of frailty or neurodegeneration. The boundary condition is therefore the time-horizon of the inflammatory insult — acute (< 28 days) appears responsive, chronic (years to decades) does not. Resolving the tension would require a chronic-exposure RCT with frailty or cognitive endpoints at 5-10 years, ideally stratified by baseline inflammatory biomarkers; such a trial does not currently appear in the corpus and the chronic null should not be overinterpreted as evidence of no effect without it.\n\nAnother tension runs through the cardiometabolic evidence base, where aspirin shows a context-dependent profile that defies a single causal sentence. Yet Ma 2021a reports that in diabetes patients the pooled evidence favors aspirin for primary prevention of cardiovascular events and mortality, and Wu 2024 finds that continuous aspirin use in hemodialysis patients with peripheral artery disease lowers all-cause mortality and cardiovascular events compared to lower adherence (P < 0.05, P = 0.02). Seidu 2019 likewise supports aspirin benefit in T2DM primary prevention. The mechanism most plausibly underwriting this divergence is baseline absolute cardiovascular risk: in the lowest-risk populations (ALLHAT, mixed primary-prevention samples), the absolute risk reduction is small relative to bleeding harm and the net effect appears null; in higher-risk populations (T2DM, hemodialysis with PAD), the absolute risk reduction is large enough to outweigh bleeding. Resolving the question would require risk-stratified RCTs with pre-specified subgroups by ASCVD risk score; in their absence, the corpus can be interpreted as showing that aspirin's cardiometabolic effect is conditional on baseline risk rather than universal.\n\nA fifth and somewhat narrower tension concerns aspirin's safety profile — specifically, whether its bleeding and renal signals are clinically meaningful or whether they are dominated by indication effects that mask the benefit. The mechanism underwriting this divergence is that aspirin's harm and benefit operate through the same pathway (irreversible COX-1 acetylation of platelet thromboxane A2) but in opposite vascular beds — antithrombotic in arteries, hemorrhagic in microvasculature under hypertension or stress. The boundary condition is comorbidity load and acute physiologic state; in stable chronic users, the bleed signal is dominated by indication; in acute inflammatory or hypertensive states, the harm signal becomes directly observable. Resolution requires that safety be reported jointly with benefit in each clinical context, not pooled across heterogeneous populations as some of the meta-analytic entries in this corpus have done. Until then, aspirin's safety profile should be treated as context-contingent rather than fixed, and any framing of aspirin as uniformly safe (e. For example, Lembo 2025's prediabetes finding that low-dose aspirin halves incident T2DM) must carry the bleeding caveat explicitly.\n\nFinally, the integrative tension across the entire corpus is that aspirin's strongest observational signals — cancer-specific mortality reduction, acute-COVID survival benefit, sepsis-associated encephalopathy survival, T2DM primary prevention — cluster in populations characterized by elevated baseline inflammation, elevated thrombotic risk, or both, while its chronic-aging signals (frailty, dementia, primary prevention in low-risk adults) are null. The mechanistic reading is that aspirin's anti-aging potential, to the extent one exists, is concentrated in the intersection of inflammation and thrombosis rather than in the slow, multi-decade biology of aging itself. This reading is consistent with the anisotropy reported across the cross-study disagreement map: cross-study disagreements surface, but they are not randomly distributed — they cluster between acute-inflammatory and chronic-aging endpoints, and between high-risk and low-risk populations. The boundary condition is therefore a dual one — inflammatory or thrombotic activation, plus elevated baseline risk. Outside that boundary, the evidence base does not yet support a longevity claim, and the paper's stated thesis that the anti-aging case is incomplete is borne out by the source structure. Resolution would require a synthesis of trial designs that anchor aspirin's putative benefits to specific biological states rather than treating it as a general-purpose longevity intervention; until such a synthesis exists, the honest reading of this corpus is that aspirin is a context-dependent modulator of inflammation- and thrombosis-driven mortality rather than a general anti-aging agent.## Discussion\n\n**Thesis:** Across 55 curated reference papers, the evidence base for Aspirin shows a context-dependent profile. Positive signals appear in: longevity, contextual other. Null findings dominate: contextual other, deficiency prevalence. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Aspirin anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.\n\nThe interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.\n\n### Evidence Summary\n\nThe evidence base for this synthesis comprises 55 included sources. By directness, the breakdown is: indirect (n=31), review (n=23), protocol (n=1). 41 of 55 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.\n\nPopulations covered span 4 distinct summaries across the source set: adults; frail / sarcopenic adults; older adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.\n\n### Interpretation constraints\n\nThe discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.\n\nThe source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.\n\nThe most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.\n\nThe key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.\n\nThe resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.\n\nThis section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.\n\nAccordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.\n\n**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.\n\n## Discussion\n**Thesis:** The aspirin use effects evidence base is best interpreted as conditionally supportive rather than definitive. The evidence base contains no sources classified primarily as direct interventional hard-endpoint evidence and no sources classified primarily as mechanistic evidence, so the strongest claims concern where signals converge and where translation remains uncertain.\n\nPositive sources (Chow 2022, Wang 2021a, Sun 2019) are important, but they must be read alongside null sources (Boakye 2021, Huang 2024, Huff 2025) and negative sources (the retained evidence base). This comparison keeps the discussion from converting selected favorable findings into a over-broad aging-related conclusion.\n\nThe practical implication is a calibrated research position. Aspirin use effects may justify further targeted testing when the mechanistic rationale, clinical endpoint, and population risk profile align, but the present corpus does not justify claims that ignore the null or adverse parts of the evidence base.\n\nThe favorable evidence should therefore be read as endpoint-specific rather than global. Signals in the longevity, contextual adjacent evidence, safety and comorbidity outcome classes can justify continued mechanistic and clinical follow-up, but they do not cancel null results in the contextual adjacent evidence, deficiency prevalence and cardiometabolic outcome classes or adverse results in no dominant outcome class. That distinction is especially important for aging claims, where a short-term biomarker shift is not equivalent to a durable improvement in function, disability, morbidity, or survival.\n\nThe most useful next trial would make this boundary explicit: predefine the endpoint layer, preserve clinically relevant function while testing metabolic benefit, track adherence over long enough follow-up to detect decay, and report null or negative results with the same prominence as favorable signals. A study designed this way would test the tradeoff directly instead of asking readers to infer it across heterogeneous populations, comparators, and outcome definitions.\n\nInterpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\nWhere coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\nThis conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\nThe study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\nThe resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\n**Resolution criteria:** No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\n## Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nThe curated corpus is dominated by observational cohorts, post-hoc analyses, and aggregated meta-analyses of such designs, which constrains the strength of any causal inference. No large primary-prevention randomized trial in healthy non-diabetic adults with hard cardiovascular or all-cause mortality endpoints is directly represented in the source set; the closest long-term mortality evidence comes from meta-analyses of secondary-prevention and high-risk populations (Desai 2020; Ma 2021a; Seidu 2019), leaving the headline longevity claim under-supported for the general adult population. Bleeding and harm outcomes are similarly under-sampled — Wong 2022 is the principal propensity-matched safety contribution, with Aoun 2017 contributing intracerebral-hemorrhage data in a narrow hemodialysis subgroup — so the risk-side of any benefit-risk statement rests on a thin evidentiary base.\n\nSeveral clinically relevant outcomes are touched by only a single source, which means those findings cannot be replicated within the corpus and should be treated as hypothesis-generating rather than confirmatory. Because each of these single-study signals carries its own design biases (selection of aspirin users, immortal-time bias, indication confounding), the corpus offers no internal replication to distinguish a true effect from a design artifact.\n\nSeveral additional reviews (Baker 2023; Li 2021b; Lin 2021; Man 2021; Harewood 2021; Memel 2020; Liang 2020; Yan 2022; Li 2021c; Gewurz 2024) carry the explicit tag \"N/A (mechanistic / indirect — no enrolled clinical population)\", meaning they contribute pooled estimates without primary patient-level data.\n\nEndpoint coverage is markedly uneven across the source set. Mortality and survival endpoints are well represented (Lin 2020; Shahrivar 2022; Liu 2021; Huang 2025; Chow 2022; Srinivasan 2022; Chow 2021; Abul 2022), but functional aging endpoints — gait speed, grip strength, sarcopenia incidence, fall frequency — are essentially absent; only Gewurz 2024 surfaces frailty as an outcome, and functional-capacity thresholds such as the EWGSOP2 grip-strength cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019) or the 0.8 m/s gait-speed frailty marker (Studenski 2011) are not directly evaluated by any source. Likewise, no source reports a validated quality-of-life or health-span composite, so claims about \"anti-aging\" extrapolate from cancer-mortality and cardiovascular-event reductions rather than from measured aging biology.\n\nSeveral clinically actionable claims rest on mechanistic or indirect evidence rather than human trials of the clinical endpoint itself. Colorectal-cancer risk reduction (Wang 2021a; Harewood 2021), hepatocellular carcinoma incidence in viral hepatitis (Li 2021b; Memel 2020), bladder-cancer risk (Fan 2021), pancreatic-cancer risk (Sun 2019), and breast-cancer incidence (Ma 2021b; Cao 2020) are inferred from pooled cohort and case-control associations, where indication for aspirin prescription and healthy-user bias are not randomized away. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.\n\nThe closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.\n\nThe practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.\n\n## What This Synthesis Adds\n\nThis synthesis maps 55 included sources on Aspirin Use Effects across 9 outcome classes and 33 cross-study disagreements. It separates endpoint-specific evidence from broad endpoint-specific protective effects claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.\n\nAcross 55 curated reference papers, the evidence base for Aspirin shows a context-dependent profile. Positive signals appear in: longevity, contextual other. Null findings dominate: contextual other, deficiency prevalence. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.\n\nThe strongest unresolved contrast is the null vs positive between Wong 2022 and Desai 2020 on safety and comorbidity (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.\n\nPrior reviews in the corpus (Lin 2020, Xiao 2021, Wang 2021a, Srinivasan 2022, Ma 2021b) emphasize convergent signals on Aspirin Use Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n### Boundary-Condition Matrix\n\n| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| longevity | 0 | 18 | mixed, null, positive, unclear | conflict-resolution gap |\n| cardiometabolic | 0 | 1 | null | direct interventional hard-endpoint gap |\n| immune and inflammation | 0 | 1 | unclear | direct interventional hard-endpoint gap |\n| contextual adjacent evidence | 0 | 23 | mixed, null, positive, unclear | conflict-resolution gap |\n| safety and comorbidity | 0 | 4 | mixed, null, positive, unclear | conflict-resolution gap |\n| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |\n| dosing and pharmacokinetics | 0 | 1 | unclear | direct interventional hard-endpoint gap |\n| immune and inflammation | 0 | 2 | positive, unclear | direct interventional hard-endpoint gap |\n| mortality and survival | 0 | 4 | unclear | direct interventional hard-endpoint gap |\n\n### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | longevity: conflict-resolution gap | 0 direct and 18 indirect sources; direction profile: mixed, null, positive, unclear |\n| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P3 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |\n| P4 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 23 indirect sources; direction profile: mixed, null, positive, unclear |\n| P5 | safety and comorbidity: conflict-resolution gap | 0 direct and 4 indirect sources; direction profile: mixed, null, positive, unclear |\n\n### Next-Study Design Recommendation\n\nThe next high-yield study for Aspirin Use Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.\n\n## Evidence Snapshot\n\nThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.\n\n### Load-Bearing Included Studies\n\n- Lin 2020; tier=B1; directness=review; endpoint=mortality survival; direction=unclear.\n- Xiao 2021; tier=B1; directness=review; endpoint=longevity; direction=unclear.\n- Wang 2021a; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.\n- Srinivasan 2022; tier=B1; directness=review; endpoint=longevity; direction=positive;\n- Ma 2021b; tier=B1; directness=review; endpoint=longevity; direction=unclear.\n- Li 2021c; tier=B1; directness=review; endpoint=longevity; direction=positive; representative statistic=P < 0.001.\n- Chow 2021; tier=B1; directness=review; endpoint=longevity; direction=positive; representative statistic=P = 0.005.\n- Abul 2022; tier=B1; directness=review; endpoint=longevity; direction=unclear.\n- Wang 2021b; tier=B1; directness=review; endpoint=longevity; direction=unclear.\n- Gewurz 2024; tier=B1; directness=review; endpoint=immune; direction=unclear; representative statistic=P > 0.05.\n\n### Source Classification Map\n\nEach retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.\n\n- Lin 2020: outcome=mortality survival; directness=review; tier=B1; direction=unclear; claims=181.\n- Xiao 2021: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=93.\n- Wang 2021a: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=positive; claims=92.\n- Srinivasan 2022: outcome=longevity; directness=review; tier=B1; direction=positive; claims=31.\n- Ma 2021b: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=8.\n- Li 2021c: outcome=longevity; directness=review; tier=B1; direction=positive; claims=7.\n- Chow 2021: outcome=longevity; directness=review; tier=B1; direction=positive; claims=6.\n- Abul 2022: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=4.\n- Wang 2021b: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=2.\n- Gewurz 2024: outcome=immune; directness=review; tier=B1; direction=unclear; claims=1.\n- Sancar 2022: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=107.\n- Fan 2021: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=103.\n- Chow 2022: outcome=longevity; directness=indirect; tier=B2; direction=positive; claims=102.\n- Baker 2023: outcome=longevity; directness=review; tier=B2; direction=mixed; claims=99.\n- Peng 2025: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=99.\n- Boakye 2021: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=null; claims=85.\n- Huang 2024: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=81.\n- Sun 2019: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=74.\n- Lin 2021: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=mixed; claims=65.\n- Memel 2020: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=60.\n- Harewood 2021: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=50.\n- Man 2021: outcome=longevity; directness=review; tier=B2; direction=unclear; claims=50.\n- Desai 2020: outcome=safety comorbidity; directness=indirect; tier=B2; direction=positive; claims=49.\n- Liu 2021: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=48.\n- Shahrivar 2022: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=48.\n- Li 2021a: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=44.\n- Seidu 2019: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=43.\n- Zhang 2023: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=43.\n- Li 2021b: outcome=immune inflammation; directness=review; tier=B2; direction=unclear; claims=41.\n- Razavi 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=41.\n- Cao 2020: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=38.\n- Huff 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=38.\n- Lembo 2025: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=38.\n- Luo 2025: outcome=safety comorbidity; directness=indirect; tier=B2; direction=mixed; claims=38.\n- Yan 2022: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=32.\n- Su 2022: outcome=longevity; directness=review; tier=B2; direction=unclear; claims=30.\n- Choi 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=29.\n- Huang 2025: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=29.\n- Celik 2021: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=28.\n- Alabsi 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=26.\n\n### Classification Criteria\n\n- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\n- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\n- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\n- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.\n\n### Load-Bearing Tensions\n\n- Severity 4 null vs positive: Wong 2022 vs Desai 2020; Desai 2020 (positive on safety comorbidity) vs Wong 2022 (null on safety comorbidity) — partial conflict\n- Severity 4 null vs positive: Alabsi 2023 vs Sun 2019; Sun 2019 (positive on contextual other) vs Alabsi 2023 (null on contextual other) — partial conflict\n- Severity 4 null vs positive: Alabsi 2023 vs Wang 2021a; Wang 2021a (positive on contextual other) vs Alabsi 2023 (null on contextual other) — partial conflict\n- Severity 4 null vs positive: Wu 2024 vs Celik 2018; Wu 2024 (positive on longevity) vs Celik 2018 (null on longevity) — partial conflict\n- Severity 4 null vs positive: Huff 2025 vs Sun 2019; Sun 2019 (positive on contextual other) vs Huff 2025 (null on contextual other) — partial conflict\n- Severity 4 null vs positive: Huff 2025 vs Wang 2021a; Wang 2021a (positive on contextual other) vs Huff 2025 (null on contextual other) — partial conflict\n- Severity 4 null vs positive: Xu 2026 vs Celik 2018; Xu 2026 (positive on longevity) vs Celik 2018 (null on longevity) — partial conflict\n- Severity 4 null vs positive: Celik 2018 vs Chow 2022; Chow 2022 (positive on longevity) vs Celik 2018 (null on longevity) — partial conflict\n\n## Conclusion\n\nThe conclusion is narrower: the retained evidence maps associations, mechanisms, and candidate endpoints for follow-up; it does not establish clinical benefit, therapeutic actionability, or anti-aging efficacy. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent/context evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.\n\nAdditional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Oldenburg 2021, Luepker 2022, Yosefzadeh 2024, Clarke 2022, Orchard 2021, Okunrintemi 2021.\n\n## References\n\n- **Lin 2020.** _Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis._ BMC Cancer, 2020. DOI: 10.1186/s12885-020-07117-4 PMID: 32646396.\n- **Sancar 2022.** _An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey._ Anatolian Journal of Cardiology, 2022. DOI: 10.5152/AnatolJCardiol.2021.541 PMID: 35435837.\n- **Fan 2021.** _Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment._ Frontiers in Oncology, 2021. DOI: 10.3389/fonc.2021.633462 PMID: 34350107.\n- **Chow 2022.** _Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19._ JAMA Network Open, 2022. DOI: 10.1001/jamanetworkopen.2022.3890 PMID: 35323950.\n- **Baker 2023.** _Aspirin Use and Survival Among Patients With Breast Cancer: A Systematic Review and Meta-Analysis._ The Oncologist, 2023. DOI: 10.1093/oncolo/oyad186 PMID: 37358878.\n- **Peng 2025.** _Regular aspirin use, breast tumor characteristics and long-term breast cancer survival._ NPJ Breast Cancer, 2025. DOI: 10.1038/s41523-025-00775-2 PMID: 40595613.\n- **Xiao 2021.** _Timing of Aspirin Use Among Patients With Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis._ JNCI Cancer Spectrum, 2021. DOI: 10.1093/jncics/pkab067 PMID: 34514327.\n- **Wang 2021a.** _Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials._ Frontiers in Oncology, 2021. DOI: 10.3389/fonc.2021.690219 PMID: 34277434.\n- **Boakye 2021.** _Aspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with use._ American Journal of Preventive Cardiology, 2021. DOI: 10.1016/j.ajpc.2021.100256 PMID: 34632437.\n- **Huang 2024.** _US population qualifying for aspirin use for primary prevention of cardiovascular disease._ American Journal of Preventive Cardiology, 2024. DOI: 10.1016/j.ajpc.2024.100669 PMID: 38681065.\n- **Sun 2019.** _Aspirin use and pancreatic cancer risk._ Medicine, 2019. DOI: 10.1097/MD.0000000000018033 PMID: 31860953.\n- **Lin 2021.** _Impact of aspirin use on clinical outcomes in patients with vasospastic angina: a systematic review and meta-analysis._ BMJ Open, 2021. DOI: 10.1136/bmjopen-2021-048719 PMID: 34326051.\n- **Memel 2020.** _Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta‐analysis._ Hepatology Communications, 2020. DOI: 10.1002/hep4.1640 PMID: 33437907.\n- **Man 2021.** _Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis._ Frontiers in Oncology, 2021. DOI: 10.3389/fonc.2020.575831 PMID: 33598421.\n- **Harewood 2021.** _Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis._ Cancer Causes & Control, 2021. DOI: 10.1007/s10552-021-01472-8 PMID: 34224060.\n- **Desai 2020.** _Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis._ The Journal of Clinical Hypertension, 2020. DOI: 10.1111/jch.14091 PMID: 33340443.\n- **Liu 2021.** _Effect of aspirin use on survival benefits of breast cancer patients._ Medicine, 2021. DOI: 10.1097/MD.0000000000026870 PMID: 34414938.\n- **Shahrivar 2022.** _Low‐dose aspirin use and colorectal cancer survival in 32,195 patients—A national cohort study._ Cancer Medicine, 2022. DOI: 10.1002/cam4.4859 PMID: 35717628.\n- **Li 2021a.** _Aspirin Use on Incident Dementia and Mild Cognitive Decline: A Systematic Review and Meta-Analysis._ Frontiers in Aging Neuroscience, 2021. DOI: 10.3389/fnagi.2020.578071 PMID: 33613260.\n- **Zhang 2023.** _Efficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke._ World Journal of Clinical Cases, 2023. DOI: 10.12998/wjcc.v11.i32.7814 PMID: 38073696.\n- **Seidu 2019.** _Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials._ Cardiovascular Diabetology, 2019. DOI: 10.1186/s12933-019-0875-4 PMID: 31159806.\n- **Razavi 2024.** _Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)._ American Journal of Preventive Cardiology, 2024. DOI: 10.1016/j.ajpc.2024.100674 PMID: 38741703.\n- **Li 2021b.** _Aspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies._ Frontiers in Medicine, 2021. DOI: 10.3389/fmed.2020.569759 PMID: 33490093.\n- **Lembo 2025.** _Daily low dose aspirin halves incident type 2 diabetes in elderly subjects with prediabetes: a five-year longitudinal cohort study in a real-word population._ Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-02802-9 PMID: 40533771.\n- **Luo 2025.** _Aspirin use is associated with attenuated risk of severe acute kidney injury in septic patients: a dual-center retrospective analysis from MIMIC-IV and eICU cohorts._ Renal Failure, 2025. DOI: 10.1080/0886022X.2025.2568650 PMID: 41077850.\n- **Huff 2025.** _Analysis of prenatal medication use and placental epigenetic gestational age in extremely low gestational age newborns (ELGANs) highlight relationships to aspirin use during pregnancy._ Clinical Epigenetics, 2025. DOI: 10.1186/s13148-025-01988-9 PMID: 41291914.\n- **Cao 2020.** _Aspirin might reduce the incidence of breast cancer._ Medicine, 2020. DOI: 10.1097/MD.0000000000021917 PMID: 32957311.\n- **Yan 2022.** _Association Between Aspirin Usage and Age-Related Macular Degeneration: An Updated Systematic Review and Meta-analysis._ Frontiers in Pharmacology, 2022. DOI: 10.3389/fphar.2022.824745 PMID: 35401184.\n- **Srinivasan 2022.** _Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis._ American Heart Hournal Plus: Cardiology Research and Practice, 2022. DOI: 10.1016/j.ahjo.2022.100191 PMID: 35971534.\n- **Su 2022.** _Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis._ Frontiers in Pharmacology, 2022. DOI: 10.3389/fphar.2022.989903 PMID: 36278186.\n- **Choi 2025.** _Effect of aspirin use on conversion risk from mild cognitive impairment to Alzheimer’s disease._ Frontiers in Aging Neuroscience, 2025. DOI: 10.3389/fnagi.2025.1603892 PMID: 40842647.\n- **Huang 2025.** _Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study._ Annals of Medicine, 2025. DOI: 10.1080/07853890.2025.2573146 PMID: 41103259.\n- **Celik 2021.** _Inappropriate Use of Aspirin in Real-Life Cardiology Practice: Results from the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) Study._ Balkan Medical Journal, 2021. DOI: 10.5152/balkanmedj.2021.21143 PMID: 34142960.\n- **Alabsi 2023.** _Regular aspirin use among a sample of American Indians/Alaskan Natives in the Upper Midwest region of the United States._ Preventive Medicine Reports, 2023. DOI: 10.1016/j.pmedr.2023.102571 PMID: 38222307.\n- **Xu 2026.** _Effect of pre-ICU aspirin use on neuroinflammation and outcomes in patients with sepsis-associated encephalopathy._ Frontiers in Neurology, 2026. DOI: 10.3389/fneur.2026.1708039 PMID: 41704889.\n- **Oldenburg 2021.** _Promoting Aspirin Use for Cardiovascular Disease Prevention Among an Adult Internet-Using Population: A Pilot Study._ Frontiers in Public Health, 2021. DOI: 10.3389/fpubh.2021.500296 PMID: 33796492.\n- **Ma 2021a.** _Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis._ Frontiers in Endocrinology, 2021. DOI: 10.3389/fendo.2021.741374 PMID: 34539583.\n- **Liang 2020.** _Association Between Prior Aspirin Use and Acute Respiratory Distress Syndrome Incidence in At-Risk Patients: A Systematic Review and Meta-Analysis._ Frontiers in Pharmacology, 2020. DOI: 10.3389/fphar.2020.00738 PMID: 32508656.\n- **Luepker 2022.** _Association of a Community Population and Clinic Education Intervention Program With Guideline-Based Aspirin Use for Primary Prevention of Cardiovascular Disease._ JAMA Network Open, 2022. DOI: 10.1001/jamanetworkopen.2022.11107 PMID: 35536579.\n- **Wu 2024.** _Continuous aspirin treatment improves cardiovascular events and all-cause mortality in hemodialysis patients with peripheral artery disease._ Renal Failure, 2024. DOI: 10.1080/0886022X.2024.2380754 PMID: 39039846.\n- **Yosefzadeh 2024.** _Impact of prior aspirin use on left ventricular function in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: An echocardiographic evaluation._ Journal of Cardiovascular and Thoracic Research, 2024. DOI: 10.34172/jcvtr.33184 PMID: 39430282.\n- **Clarke 2022.** _Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta‐analysis._ European Journal of Neurology, 2022. DOI: 10.1111/ene.15433 PMID: 35652757.\n- **Li 2024.** _The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis._ Human Genomics, 2024. DOI: 10.1186/s40246-024-00699-1 PMID: 39617913.\n- **Celik 2018.** _Design and rationale for the ASSOS study: Appropriateness of aspirin use in medical outpatients a multicenter and observational study._ Anatolian Journal of Cardiology, 2018. DOI: 10.14744/AnatolJCardiol.2018.47587 PMID: 30504736.\n- **Wong 2022.** _Safety of Continuing Aspirin Use in Cervical Laminoplasty: A Propensity Score-Matched Analysis._ Spine Surgery and Related Research, 2022. DOI: 10.22603/ssrr.2022-0163 PMID: 37041877.\n- **Aoun 2017.** _Reduction of intracerebral hemorrhage in hemodialysis patients after reducing aspirin use: A quality-assurance observational study._ PLoS ONE, 2017. DOI: 10.1371/journal.pone.0185847 PMID: 28968454.\n- **Gong 2025.** _Aspirin improves short and long term survival outcomes of patients with sepsis associated encephalopathy._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-08075-2 PMID: 40595183.\n- **Orchard 2021.** _Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.2339\n- **Ma 2021b.** _Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019._ Clin Breast Cancer, 2021. DOI: 10.1016/j.clbc.2021.02.005 PMID: 33741292.\n- **Li 2021c.** _Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis._ Clin Res Hepatol Gastroenterol, 2021. DOI: 10.1016/j.clinre.2020.09.006 PMID: 33067170.\n- **Chow 2021.** _Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019._ Anesth Analg, 2021. DOI: 10.1213/ane.0000000000005292 PMID: 33093359.\n- **Abul 2022.** _Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes._ medRxiv preprint, 2022. DOI: 10.1101/2022.08.03.22278392\n- **Okunrintemi 2021.** _Shared decision making and patient reported outcomes among adults with atherosclerotic cardiovascular disease, medical expenditure panel survey 2006–2015._ American Journal of Preventive Cardiology, 2021. DOI: 10.1016/j.ajpc.2021.100281 PMID: 34877558.\n- **Wang 2021b.** _Low-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort studies._ J Public Health (Oxf), 2021. DOI: 10.1093/pubmed/fdz114 PMID: 31781767.\n- **Gewurz 2024.** _Inflammation, Frailty, and Aspirin Use in the Physicians' Health Study: A Pilot Study._ J Frailty Aging, 2024. DOI: 10.14283/jfa.2024.37 PMID: 39574285.\n\n### Background References\n\n*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*\n\n- **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923 PMID: 21205966.\n- **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169 PMID: 30312372.\n- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124 PMID: 16060722.\n","metadata":{"abstract":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Aspirin remains one of the most widely used medications globally, yet its effects beyond cardiovascular prophylaxis — including on cancer incidence and survival, infection-related mortality, and aging-relevant outcomes — remain actively debated as guidelines shift and observational cohorts proliferate. We conducted an AI-assisted structured evidence synthesis across 55 curated reference papers indexed for Aspirin, extracting effect estimates, confidence intervals, and p-values into an audit-trailed evidence table while preserving the design and directness annotations supplied by the original sources. For COVID-19, pooled analyses of hospitalized patients indicated that aspirin use was independently associated with reduced in-hospital mortality (P = 0.007), mechanical ventilation, and ICU admission, although a parallel meta-analysis limited to randomized controlled trials found no statistically significant effect on all-cause mortality. Safety signals include increased intracerebral hemorrhage when aspirin was combined with severe hypertension (P = 0.","source_title":"Adjacent Evidence Brief: Aspirin Use Effects — full paper","article_type":"rapid_evidence_synthesis","publication_class":"adjacent_evidence_brief","evidence_profile":{"weak_evidence_ratio":0.0,"direct_clinical_sources":null,"source_count":55,"primary_source_ratio":0.5818,"mixed_signal":true,"non_supportive_signal":true,"indirect_signal":true},"counts":{"retrieved_count":55,"selected_count":55,"review_like_count":23,"primary_like_count":32,"year_start":2017,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":{"recommendation":"pass","available":true,"checked_at":"2026-07-04T13:10:37.538884+00:00","reason":"integrity_self_match_ignored","matched_publication_id":null,"duplication_score":null,"similarity_score":0.0,"plagiarism_flag":false,"matched_sources":[],"breakdown":{"semantic_similarity":1.0,"citation_overlap_excluding_foundational":1.0,"external_similarity":0.0},"feedback_for_agent":null,"attempts":1,"self_match_ignored":true},"public_visibility":"listed","source_submission_id":"41cdf7a6-2dd8-48c0-845a-28adbb71f25f","submission_identity_key":"sha256:e27513b07600873dd1c1161b2c44c845c4841a65d3d700b81c14aafa1f27ae27","submission_payload_hash":"sha256:29e95be3d69fdfb38e4eb6cef2874f46ddd0578a01097f8e0712b3f60161c66f","content_hash":"sha256:662eb75607bfdba01b29302e8bca263d99248e5a98ade3e9779acb2a7d232262","source_citation_hash":"sha256:d073ab431b2c3e1694e4c3afc27ce2f1e7fc0693d8f17811d3e38bf97890efc0","author_signature":"sha256:662eb75607bfdba01b29302e8bca263d99248e5a98ade3e9779acb2a7d232262","run_id":"synthesis-aspirin_use_effects-v06-DAILY-2026-06-30T13-49-18Z-R2","topic":"aspirin_use_effects","domain_slug":"longevity","category":"longevity","identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/A8HGK","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"a8hgk","osf_url":"https://osf.io/a8hgk/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"a8hgk","url":"https://osf.io/a8hgk/","doi":"10.17605/OSF.IO/A8HGK"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"MiniMax-M3|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_3ad4ceb02a5f4cce","dw_chain_url":"https://provenance.researka.org/artifacts/claim_3ad4ceb02a5f4cce/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_3ad4ceb02a5f4cce/chain","dw_source_artifact_id":"source_8efd88f2232b4a63","dw_input_artifact_ids":["source_eee891d714ae4faf","source_e06fe623105f4b1d","source_660064f5f36d4bd2","source_81d45aff07ac45c0","source_f3f391ef95e54b09","source_390db79a300a473f"],"dw_step_id":"step_831c829ba3ba4724","dw_step_hash":"3444f46b8aa4330a656befcef20078436fc9231a8ba7fc9beb586f8d08c9271e","dw_status":"registered","sha256":"sha256:59b38f5dac7738acf573913921a4419ed6da54ef0060352b4bb574f50d17ba44"},"created_at":"2026-07-04T10:16:38.691635+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"145fcccc-2360-4120-8674-34dd3e97ade7","traces":[{"claim_id":"claim_1","claim":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Aspirin remains one of the most widely used medications globally, yet its effects beyond cardiovascular prophylaxis — including on cancer incidence and survival, infection-related mortality, and aging-relevant outcomes — remain actively debated as guidelines shift and observational cohorts proliferate. We conducted an AI-assisted structured evidence synthesis across 55 curated reference papers indexed for Aspirin, extracting effect estimates, confidence intervals, and p-values into an audit-trailed evidence table while preserving the design and directness annotations supplied by the original sources. For COVID-19, pooled analyses of hospitalized patients indicated that aspirin use was independently associated with reduced in-hospital mortality (P = 0.007), mechanical ventilation, and ICU admission, although a parallel meta-analysis limited to randomized controlled trials found no statistically significant effect on all-cause mortality. Safety signals include increased intracerebral hemorrhage when aspirin was combined with severe hypertension (P = 0.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_2","claim":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_3","claim":"We conducted an AI-assisted structured evidence synthesis across 55 curated reference papers indexed for Aspirin, extracting effect estimates, confidence intervals, and p-values into an audit-trailed evidence table while preserving the design and directness annotations supplied by the original sources.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_4","claim":"Safety signals include increased intracerebral hemorrhage when aspirin was combined with severe hypertension (P = 0.003), whereas aspirin exposure was associated with lower severe AKI incidence in MIMIC-IV/eICU sepsis cohorts (P < 0.001), illustrating outcome- and population-dependent benefit–risk tradeoffs.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_5","claim":"Across outcome classes, cross-study disagreements emerged in the synthesis — most prominently null-versus-positive conflicts on contextual outcomes (Sun 2019 vs Alabsi 2023; Wang 2021a vs Huff 2025) and on longevity outcomes in specific subgroups (Wu 2024, Xu 2026, Chow 2022 vs Celik 2018) — confirming that aspirin's effect profile is context-dependent rather than uniformly beneficial.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_6","claim":"Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_7","claim":"This synthesis evaluates evidence on aspirin use effects across 55 included source papers and 2311 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_8","claim":"The corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 55 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_9","claim":"The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_10","claim":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_11","claim":"The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_12","claim":"Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_13","claim":"Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_14","claim":"The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_15","claim":"For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_16","claim":"The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_17","claim":"The background evidence for aspirin use effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as the retained evidence base are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_18","claim":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_19","claim":"Across the retained sources, positive signals cluster around the longevity, contextual adjacent evidence, safety and comorbidity outcome classes; null signals around the contextual adjacent evidence, deficiency prevalence and cardiometabolic outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_20","claim":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_21","claim":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_22","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_23","claim":"Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_24","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_25","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_26","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_27","claim":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_28","claim":"| Aspirin Use Effects / Contextual Adjacent Evidence | n=23; claims=984 | significant source statistic in 16/23 sources; receipt-level direction coded unclear | 14 indirect; 9 review | limited corpus depth in this outcome class |","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_29","claim":"| Aspirin Use Effects / Cardiometabolic | n=1; claims=81 | significant source statistic in 1/1 sources; receipt-level direction coded null | 1 indirect | single-source slice; hypothesis-generating |","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_30","claim":"Contextual Adjacent Evidence: n=23; claims=984; mixed signal in 15/23 sources | directness: 14 indirect; 9 review; main limitation: no direct clinical anchor.","citation_support":[],"candidate_sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175).","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","source_id":"source_5","support_kind":"candidate_source_row"}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"145fcccc-2360-4120-8674-34dd3e97ade7","content_hash":"sha256:662eb75607bfdba01b29302e8bca263d99248e5a98ade3e9779acb2a7d232262","nodes":[{"id":"145fcccc-2360-4120-8674-34dd3e97ade7","type":"publication","title":"Adjacent Evidence Brief: Aspirin Use Effects — full paper"},{"id":"claim_1","type":"claim","text":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Aspirin remains one of the most widely used medications globally, yet its effects beyond cardiovascular prophylaxis — including on cancer incidence and survival, infection-related mortality, and aging-relevant outcomes — remain actively debated as guidelines shift and observational cohorts proliferate. We conducted an AI-assisted structured evidence synthesis across 55 curated reference papers indexed for Aspirin, extracting effect estimates, confidence intervals, and p-values into an audit-trailed evidence table while preserving the design and directness annotations supplied by the original sources. For COVID-19, pooled analyses of hospitalized patients indicated that aspirin use was independently associated with reduced in-hospital mortality (P = 0.007), mechanical ventilation, and ICU admission, although a parallel meta-analysis limited to randomized controlled trials found no statistically significant effect on all-cause mortality. Safety signals include increased intracerebral hemorrhage when aspirin was combined with severe hypertension (P = 0."},{"id":"claim_2","type":"claim","text":"Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims."},{"id":"claim_3","type":"claim","text":"We conducted an AI-assisted structured evidence synthesis across 55 curated reference papers indexed for Aspirin, extracting effect estimates, confidence intervals, and p-values into an audit-trailed evidence table while preserving the design and directness annotations supplied by the original sources."},{"id":"claim_4","type":"claim","text":"Safety signals include increased intracerebral hemorrhage when aspirin was combined with severe hypertension (P = 0.003), whereas aspirin exposure was associated with lower severe AKI incidence in MIMIC-IV/eICU sepsis cohorts (P < 0.001), illustrating outcome- and population-dependent benefit–risk tradeoffs."},{"id":"claim_5","type":"claim","text":"Across outcome classes, cross-study disagreements emerged in the synthesis — most prominently null-versus-positive conflicts on contextual outcomes (Sun 2019 vs Alabsi 2023; Wang 2021a vs Huff 2025) and on longevity outcomes in specific subgroups (Wu 2024, Xu 2026, Chow 2022 vs Celik 2018) — confirming that aspirin's effect profile is context-dependent rather than uniformly beneficial."},{"id":"claim_6","type":"claim","text":"Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence."},{"id":"claim_7","type":"claim","text":"This synthesis evaluates evidence on aspirin use effects across 55 included source papers and 2311 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty."},{"id":"claim_8","type":"claim","text":"The corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 55 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence."},{"id":"claim_9","type":"claim","text":"The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation."},{"id":"claim_10","type":"claim","text":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance."},{"id":"claim_11","type":"claim","text":"The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof."},{"id":"claim_12","type":"claim","text":"Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection."},{"id":"claim_13","type":"claim","text":"Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints."},{"id":"claim_14","type":"claim","text":"The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific."},{"id":"claim_15","type":"claim","text":"For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint."},{"id":"claim_16","type":"claim","text":"The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge."},{"id":"claim_17","type":"claim","text":"The background evidence for aspirin use effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as the retained evidence base are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation."},{"id":"claim_18","type":"claim","text":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect."},{"id":"claim_19","type":"claim","text":"Across the retained sources, positive signals cluster around the longevity, contextual adjacent evidence, safety and comorbidity outcome classes; null signals around the contextual adjacent evidence, deficiency prevalence and cardiometabolic outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation."},{"id":"claim_20","type":"claim","text":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty."},{"id":"claim_21","type":"claim","text":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support."},{"id":"claim_22","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text."},{"id":"claim_23","type":"claim","text":"Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification."},{"id":"claim_24","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_25","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_26","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_27","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_28","type":"claim","text":"| Aspirin Use Effects / Contextual Adjacent Evidence | n=23; claims=984 | significant source statistic in 16/23 sources; receipt-level direction coded unclear | 14 indirect; 9 review | limited corpus depth in this outcome class |"},{"id":"claim_29","type":"claim","text":"| Aspirin Use Effects / Cardiometabolic | n=1; claims=81 | significant source statistic in 1/1 sources; receipt-level direction coded null | 1 indirect | single-source slice; hypothesis-generating |"},{"id":"claim_30","type":"claim","text":"Contextual Adjacent Evidence: n=23; claims=984; mixed signal in 15/23 sources | directness: 14 indirect; 9 review; main limitation: no direct clinical anchor."},{"id":"source_1","type":"source","study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","year":2020,"doi":"10.1186/s12885-020-07117-4","url":"https://doi.org/10.1186/s12885-020-07117-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2020","excerpt":"BACKGROUND: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. METHODS: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. RESULTS: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers."},{"id":"source_2","type":"source","study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","year":2022,"doi":"10.5152/AnatolJCardiol.2021.541","url":"https://doi.org/10.5152/AnatolJCardiol.2021.541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sancar 2022","excerpt":"BACKGROUND: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial has been the largest study ever conducted among patients in Turkey regarding aspirin treatment. In the subgroup analysis of the hypertensive group of the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial, we aimed to evaluate the physicians' adherence to current guidelines regarding their aspirin treatment preferences. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study trial is a cross-sectional and multicenter study conducted among 5007 consecutive patients aged ≥18 years. The study population consisted of outpatients on aspirin treatment (80-300 mg). The patient data were obtained from 30 different cardiology clinics of 14 cities from all over Turkey. In this subgroup analysis, patients were divided into 2 groups: the hypertensive group (n=3467, 69.3%) and the group without hypertension (n=1540, 30.7%) according to the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the Management of Arterial Hypertension."},{"id":"source_3","type":"source","study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","year":2021,"doi":"10.3389/fonc.2021.633462","url":"https://doi.org/10.3389/fonc.2021.633462","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Fan 2021","excerpt":"Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa ( P =0.175)."},{"id":"source_4","type":"source","study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","year":2022,"doi":"10.1001/jamanetworkopen.2022.3890","url":"https://doi.org/10.1001/jamanetworkopen.2022.3890","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chow 2022","excerpt":"IMPORTANCE: Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE: To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of 112 269 hospitalized patients with moderate COVID-19, enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C). EXPOSURE: Aspirin use within the first day of hospitalization. MAIN OUTCOME AND MEASURES: The primary outcome was 28-day in-hospital mortality, and secondary outcomes were pulmonary embolism and deep vein thrombosis. Odds of in-hospital mortality were calculated using marginal structural Cox and logistic regression models. Inverse probability of treatment weighting was used to reduce bias from confounding and balance characteristics between groups."},{"id":"source_5","type":"source","study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","year":2025,"doi":"10.1038/s41523-025-00775-2","url":"https://doi.org/10.1038/s41523-025-00775-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Peng 2025","excerpt":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type."},{"id":"source_6","type":"source","study":"Aspirin Use and Survival Among Patients With Breast Cancer: A Systematic Review and Meta-Analysis","year":2023,"doi":"10.1093/oncolo/oyad186","url":"https://doi.org/10.1093/oncolo/oyad186","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Baker 2023","excerpt":"BACKGROUND: Previous meta-analyses have indicated that aspirin could affect breast cancer outcomes, particularly when taken post-diagnostically. However, several recent studies appear to show little to no association between aspirin use and breast cancer mortality, all-cause mortality, or recurrence. AIMS: This study aims to conduct an updated systematic review and meta-analysis on the associations of pre-diagnostic and post-diagnostic aspirin use with the aforementioned breast cancer outcomes. It also looks, through subgroup analyses and meta-regressions, at a range of variables that could explain the associations between aspirin use and breast cancer outcomes. RESULTS: In total, 24 papers and 149 860 patients with breast cancer were included. Pre-diagnostic aspirin use was not associated with breast-cancer-specific mortality (HR 0.98, 95% CI, 0.80-1.20, P = .84) or recurrence (HR 0.94, 95% CI, 0.88-1.02, P = .13). Pre-diagnostic aspirin was associated with non-significantly higher all-cause mortality (HR 1.27, 95% CI, 0.95-1.72, P = .11). Post-diagnostic aspirin was not significantly associated with all-cause mortality (HR 0.87, 95% CI, 0.71-1.07, P = .18) or recurrence (HR 0."},{"id":"source_7","type":"source","study":"Timing of Aspirin Use Among Patients With Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis","year":2021,"doi":"10.1093/jncics/pkab067","url":"https://doi.org/10.1093/jncics/pkab067","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Xiao 2021","excerpt":"BACKGROUND: Exposure of aspirin has been associated with reduced risk of colorectal cancer (CRC) incidence, but aspirin use in relation to CRC patients' mortality remains undetermined. It is necessary to quantify the association between aspirin use and CRC mortality. METHODS: Two authors independently searched the electronic databases (PubMed, Embase, and the Cochrane Library) from 1947 through April 25, 2020. All observational studies assessing the association between different timing of aspirin use and CRC mortality were included. The effect size on study outcomes was calculated using random-effect model and presented as risk ratio (RR) with 95% confidence interval (CI). Heterogeneity, publication bias, and quality of included studies were also assessed. RESULTS: A total of 34 studies were included in this systematic review and meta-analysis. Prediagnosis aspirin use was not associated with CRC-specific mortality (RR = 0.91, 95% CI = 0.79 to 1.05) and all-cause mortality (RR = 0.87, 95% CI = 0.57 to 1.31). A statistically significant association between continued aspirin use and improvement in both CRC-specific mortality (RR = 0.76, 95% CI = 0.70 to 0."},{"id":"source_8","type":"source","study":"Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials","year":2021,"doi":"10.3389/fonc.2021.690219","url":"https://doi.org/10.3389/fonc.2021.690219","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Wang 2021a","excerpt":"BACKGROUND: Whether aspirin use can decrease or increase cancer risk remains controversial. In this study, a meta-analysis of cohort studies and randomized controlled trials (RCTs) were conducted to evaluate the effect of aspirin use on common cancer risk. METHOD: Medline and Embase databases were searched to identify relevant studies. Meta-analyses of cohort studies and RCTs were performed to assess the effect of aspirin use on the risk of colorectal, gastric, breast, prostate and lung cancer. Cochran Q test and the I square metric were calculated to detect potential heterogeneity among studies. Subgroup meta-analyses according to exposure categories (frequency and duration) and timing of aspirin use (whether aspirin was used before and after cancer diagnosis) were also performed. A dose-response analysis was carried out to evaluate and quantify the association between aspirin dose and cancer risk. RESULTS: A total of 88 cohort studies and seven RCTs were included in the final analysis. Meta-analyses of cohort studies revealed that regular aspirin use reduced the risk of colorectal cancer (CRC) (RR=0.85, 95%CI: 0.78-0.92), gastric cancer (RR=0.67, 95%CI: 0.52-0."},{"id":"source_9","type":"source","study":"Aspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with use","year":2021,"doi":"10.1016/j.ajpc.2021.100256","url":"https://doi.org/10.1016/j.ajpc.2021.100256","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Boakye 2021","excerpt":"OBJECTIVE: : Aspirin has been widely utilized over several decades for atherosclerotic cardiovascular disease (ASCVD) prevention among adults in the United States. We examined trends in aspirin use among adults aged ≥40 years from 1998 to 2019 and assessed factors associated with its use for primary and secondary ASCVD prevention. METHODS: : Using 1998-2019 Behavioral Risk Factor Surveillance System data, we obtained weighted prevalence of aspirin use among adults aged ≥40 years for each year and examined trends in use over this period. Using multivariable logistic regression and utilizing data from 54,388 respondents aged ≥40 years in the 2019 data, we assessed factors associated with aspirin use for secondary prevention and for primary prevention stratified by the number of traditional ASCVD risk factors reported (hypertension, diabetes mellitus, high cholesterol, overweight/obesity, and cigarette smoking). RESULTS: : Aspirin use prevalence increased from 29.0%(95%CI, 27.9%-30.2%) in 1998 to 37.5%(36.9%-38.0%) in 2009. However, use has slightly declined over the last decade: 35.6%(34.6%-36.6%) in 2011 to 33.5%(32.5%-34.6%) in 2019."},{"id":"source_10","type":"source","study":"US population qualifying for aspirin use for primary prevention of cardiovascular disease","year":2024,"doi":"10.1016/j.ajpc.2024.100669","url":"https://doi.org/10.1016/j.ajpc.2024.100669","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Huang 2024","excerpt":"OBJECTIVE: Aspirin has been used for primary prevention of atherosclerotic cardiovascular disease (ASCVD) for decades, but this indication has become controversial with recent trial data. The 2022 US Preventive Services Task Force (USPSTF) provided a recommendation to consider aspirin use for primary prevention in adults 40-59 years with a 10-year ASCVD risk ≥10 % and not at increased risk of bleeding, yet population estimates for the impact of this recommendation are unknown. The objective of this study is to determine the prevalence and demographics of the US population who meet eligibility criteria for aspirin under the new 2022 USPSTF guidelines. METHODS: This is a serial cross-sectional study using data from the 2011-March 2020 National Health and Nutrition Examination Survey (NHANES) database. Individuals aged 40-59 years without a self-reported history of ASCVD were included. 10-year estimated ASCVD risk ≥10 % as calculated by the Pooled Cohort Equations (PCE) and increased bleeding risk determined using variables adapted from USPSTF guidelines were further applied as inclusion and exclusion criteria, respectively."},{"id":"source_11","type":"source","study":"Impact of aspirin use on clinical outcomes in patients with vasospastic angina: a systematic review and meta-analysis","year":2021,"doi":"10.1136/bmjopen-2021-048719","url":"https://doi.org/10.1136/bmjopen-2021-048719","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Lin 2021","excerpt":"OBJECTIVES: The use of aspirin to prevent cardiovascular disease in vasospastic angina (VSA) patients without significant stenosis has yet to be investigated. This study aimed to investigate the efficacy of aspirin use among VSA patients. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Web of Science and Cochrane Central Register of Controlled Trials were searched for relevant information prior to October 2020. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Aspirin use versus no aspirin use (placebo or no treatment) among VSA patients without significant stenosis. DATA EXTRACTION AND SYNTHESIS: Two investigators extracted the study data. ORs and 95% CIs were calculated and graphed as forest plots. The Newcastle-Ottawa Quality Assessment Scale tool and Begg's funnel plot were used to assess risk of bias. RESULTS: Four propensity-matched cohorts, one retrospective analysis and one prospective multicentre cohort, in total comprising 3661 patients (aspirin use group, n=1695; no aspirin use group, n=1966) were included in this meta-analysis."},{"id":"source_12","type":"source","study":"Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta‐analysis","year":2020,"doi":"10.1002/hep4.1640","url":"https://doi.org/10.1002/hep4.1640","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Memel 2020","excerpt":"Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death worldwide, with a growing incidence and poor prognosis. While some recent studies suggest an inverse association between aspirin use and reduced HCC incidence, other data are conflicting. To date, the precise magnitude of risk reduction-and whether there are dose-dependent and duration-dependent associations-remains unclear. To provide an updated and comprehensive assessment of the association between aspirin use and incident HCC risk, we conducted a systematic review and meta-analysis of all observational studies published through September 2020. Using random-effects meta-analysis, we calculated the pooled relative risks (RRs) and 95% confidence intervals (CIs) for the association between aspirin use and incident HCC risk. Where data were available, we evaluated HCC risk according to the defined daily dose of aspirin use. Among 2,389,019 participants, and 20,479 cases of incident HCC, aspirin use was associated with significantly lower HCC risk (adjusted RR, 0.61; 95% CI, 0.51-0.73; P ≤ 0.001; I 2 = 90.4%)."},{"id":"source_13","type":"source","study":"Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis","year":2021,"doi":"10.3389/fonc.2020.575831","url":"https://doi.org/10.3389/fonc.2020.575831","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Man 2021","excerpt":"BACKGROUND: Aspirin use has been suggested to reduce the incidence of ovarian cancer (OC) in women. However, previous studies regarding the association between aspirin use and mortality in women with OC showed inconsistent results. We aimed to evaluate the association between aspirin use and mortality in women with OC in a meta-analysis. METHODS: Relevant cohort studies were obtained via search of PubMed, Cochrane's Library, and Embase databases from inception to May 3, 2020. A random-effect model, which incorporates the potential heterogeneity among the included studies, was used to pool the results. Predefined stratified analyses were applied to evaluate the potential study characteristics on the outcome, including the timing of aspirin use, dose of aspirin, age of the women, and the clinical stages of the cancer. Sensitivity analysis by omitting one study at a time was used to assess the stability of the results. RESULTS: Six cohort studies including 17,981 women with OC were included. Pooled results showed that aspirin use had no statistically significant association with mortality in these patients (adjusted risk ratio [RR]: 0.85, 95% confidence interval [CI]: 0.70 to 1."},{"id":"source_14","type":"source","study":"Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis","year":2021,"doi":"10.1007/s10552-021-01472-8","url":"https://doi.org/10.1007/s10552-021-01472-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Harewood 2021","excerpt":"PURPOSE: Evidence of differences in the etiology of, and poorer survival from, proximal colon compared to the distal colorectum, necessitates research into its risk factors. This systematic review summarizes the evidence on medication use and proximal colon cancer risk. METHODS: MEDLINE and EMBASE were searched for prospective studies investigating nine medication groups, namely non-steroidal anti-inflammatory drugs (NSAIDs), exogenous hormones, i.e., hormone replacement therapy (HRT) or oral contraceptives (OCs), statins, proton pump inhibitors, anti-hypertensives, metformin (an antidiabetic), antidiarrheals or laxatives, and the risk of proximal colon cancer. Narrative synthesis and meta-analyses, using random effects models to estimate risk ratios (RRs) and 95% confidence intervals (CIs), were conducted. RESULTS: Twenty nine publications investigating NSAIDs (n = 13), exogenous hormones [HRT (n = 9) or OCs (n = 4)] statins (n = 5), anti-hypertensives (n = 1), and metformin (n = 1) were included. Summary RRs reported a protective effect of aspirin use (RR 0.80, 95% CI 0.73-0.89) but no associations between HRT (RR 0.92, 95% CI 0.83-1.02), OC (RR 1.06, 95% CI 0.98-1."},{"id":"source_15","type":"source","study":"Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis","year":2020,"doi":"10.1111/jch.14091","url":"https://doi.org/10.1111/jch.14091","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Desai 2020","excerpt":"It is unclear whether aspirin is beneficial for prevention of CVD in patients with CKD. We performed a secondary analysis of the ALLHAT trial to assess the effect of baseline aspirin use on nonfatal myocardial infarction (MI) or fatal coronary heart disease (CHD), all-cause mortality, and stroke. Baseline characteristics of aspirin users and nonusers were used to generate propensity-matched cohorts. Using conditional Cox proportional hazard regression models, we examined the effect of aspirin on the outcomes in the cohort at large and across 3 levels of kidney function (eGFR ≥90, 60-89, and <60). 11 250 ALLHAT participants reported using aspirin at baseline. The propensity-matched dataset included 6894 nonusers matched with replacement to achieve a balanced analysis population (n = 22 500). Risk of fatal CHD or nonfatal MI (HR = 0.94, 95% CI 0.86-1.02) and stroke (HR = 1.01, 95% CI 0.89-1.15) was not significantly different between groups. Aspirin users were at significantly lower risk of all-cause mortality compared to nonusers (HR = 0.82, 95% CI 0.76-0.88). Aspirin use was not associated with incidence of fatal CAD or nonfatal MI in patients with CVD (HR = 0.93, CI 0.84-1."},{"id":"source_16","type":"source","study":"Low‐dose aspirin use and colorectal cancer survival in 32,195 patients—A national cohort study","year":2022,"doi":"10.1002/cam4.4859","url":"https://doi.org/10.1002/cam4.4859","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Shahrivar 2022","excerpt":"BACKGROUND: Results from previous studies indicate that use of aspirin may improve colorectal cancer (CRC) survival. The aim of this study was to assess whether use of aspirin influences overall survival or CRC-specific survival in an unselected cohort of patients diagnosed with CRC. METHODS: The study was performed using the Colorectal Cancer Data Base Sweden (CRCBaSe), a mega-linkage originating from the Swedish Colorectal Cancer Register, with additional linkages to other national health care registers. All patients diagnosed with primary CRC stage I-III treated with curative surgery, aged 18-85 years at diagnosis, from 2007 through 2016 were identified. Information on low-dose aspirin use was extracted from the Swedish Prescribed Drug Register. Exposure was defined as dispensed prescription for at least 6 months. Aspirin exposure was analyzed at the time of surgery (yes/no) and as a time-varying exposure during follow-up. Follow-up was restricted to a maximum 6 years, to model 5-year survival. Cox regression models were fitted to estimate hazard ratios (HRs) with 95% confidence intervals (CIs)."},{"id":"source_17","type":"source","study":"Effect of aspirin use on survival benefits of breast cancer patients","year":2021,"doi":"10.1097/MD.0000000000026870","url":"https://doi.org/10.1097/MD.0000000000026870","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Liu 2021","excerpt":"OBJECTIVE: The purpose of this study is to investigate whether aspirin improves the prognosis of breast cancer patients by meta analysis. METHODS: Searched PubMed, EMBASE, and other databases for literature on the relationship between aspirin use and breast cancer prognosis, with the deadline of October 2019. The related results of all-cause death, breast cancer-specific death, and breast cancer recurrence/metastasis were extracted to combine the effect amount. The sensitivity analysis and published bias analysis were carried out for the included data. Stata12.0 software was used to complete all statistical analysis. RESULTS: A total of 13 papers were included in the study, including 142,644 breast cancer patients. The results of meta-analysis showed that patients who took aspirin were associated with lower breast cancer-specific death (HR = 0.69, 95% CI = 0.61-0.76), all-cause death (HR = 0.78, 95% CI = 0.71-0.84), and risk of recurrence/metastasis (HR = 0.91, 95% CI: 0.82-1.00). CONCLUSIONS: Aspirin use may improve all-cause mortality, specific mortality, and risk of recurrence/metastasis in patients with breast cancer."},{"id":"source_18","type":"source","study":"Aspirin Use on Incident Dementia and Mild Cognitive Decline: A Systematic Review and Meta-Analysis","year":2021,"doi":"10.3389/fnagi.2020.578071","url":"https://doi.org/10.3389/fnagi.2020.578071","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Li 2021a","excerpt":"Background: More people with cognitive dysfunction and dementia also fall into the category of high vascular risk, for which aspirin is one of the most frequently used drugs. However, previous studies reporting that aspirin buffers against mild cognitive decline (MCI) and dementia remain controversial. We thus conducted an updated systematic review and meta-analysis to evaluate the association of aspirin use with the risk of MCI and dementia in older adults. Methods: Data sources from PubMed, Embase, Web of Science, and the Cochrane Database for randomized controlled trails (RCTs) and cohort studies (published between January 1, 2000 and April 11, 2020). Relative risks (RRs) and 95% confidence intervals (95% CIs) were used to pool data on the occurrence of dementia and MCI with random-effects models. Results: Of 3,193 identified articles, 15 studies (12 cohort studies and three RCTs) were eligible and were included in our analysis, which involved a total of 100,909 participants without cognitive dysfunctions or dementia at baseline. In pooled cohort studies, aspirin use did not reduce the incidence of MCI and dementia (the pooled RR = 0.97; 95% CI = 0.85-1."},{"id":"source_19","type":"source","study":"Efficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke","year":2023,"doi":"10.12998/wjcc.v11.i32.7814","url":"https://doi.org/10.12998/wjcc.v11.i32.7814","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Zhang 2023","excerpt":"BACKGROUND: Aspirin is a widely used antiplatelet agent that reduces the risk of recurrent ischemic stroke and other vascular events. However, the optimal timing and dose of aspirin initiation after an acute stroke remain controversial. AIM: To evaluate the efficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke. METHODS: We conducted a randomized, open-label, controlled trial in 60 patients with acute ischemic or hemorrhagic stroke who were admitted to our hospital within 24 h of symptom onset. Patients were randomly assigned to receive either aspirin 300 mg daily or no aspirin within 48 h of stroke onset. The primary outcome was the occurrence of recurrent stroke, myocardial infarction, or vascular death within 90 d. The secondary outcomes were functional outcomes at 90 d measured using the modified Rankin Scale (mRS), incidence of bleeding complications, and mortality rate. RESULTS: The mean age of the patients was 67.8 years and 55% of them were male. The median time from stroke onset to randomization was 12 h. The baseline characteristics were well balanced between the two groups. The primary outcome occurred in 6."},{"id":"source_20","type":"source","study":"Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)","year":2024,"doi":"10.1016/j.ajpc.2024.100674","url":"https://doi.org/10.1016/j.ajpc.2024.100674","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Razavi 2024","excerpt":"OBJECTIVE: Lipoprotein(a) [Lp(a)] is an atherogenic and prothrombotic lipoprotein associated with atherosclerotic cardiovascular disease (ASCVD). We assessed the association between regular aspirin use and ASCVD mortality among individuals with versus without elevated Lp(a) in a nationally representative US cohort. METHODS: Eligible participants were aged 40-70 years without clinical ASCVD, reported on aspirin use, and had Lp(a) measurements from the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994), the only cycle of this nationally representative US cohort to measure Lp(a). Regular aspirin use was defined as taking aspirin ≥30 times in the previous month. Using NHANES III linked mortality records and weighted Cox proportional hazards regression, the association between regular aspirin use and ASCVD mortality was observed in those with and without elevated Lp(a) (≥50 versus <50 mg/dL) over a median 26-year follow-up. RESULTS: Among 2,990 persons meeting inclusion criteria (∼73 million US adults), the mean age was 50 years, 86% were non-Hispanic White, 9% were non-Hispanic Black, 53% were female, and 7% reported regular aspirin use."},{"id":"source_21","type":"source","study":"Aspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies","year":2021,"doi":"10.3389/fmed.2020.569759","url":"https://doi.org/10.3389/fmed.2020.569759","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Li 2021b","excerpt":"Background: The association between aspirin use and the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) or hepatitis C (HCV) virus infection remains not fully determined. A meta-analysis was performed to summarize the findings of cohort studies. Methods: Relevant cohort studies were retrieved via a search of PubMed Cochrane's Library and Embase databases. A random-effect model was used to pool the results. Subgroup analyses were performed to evaluate the influence of study characteristics on the association. Results: Seven cohort studies with 120,945 adult patients with HBV or HCV infection were included. Pooled results showed that aspirin use was independently associated with a reduced risk of HCC in these patients (risk ratio: 0.73, 95% confidence interval: 0.64 to 0.83, p < 0.001; I 2 = 86%). Subgroup analyses showed that aspirin use was associated with a reduced HCC risk regardless of the viral type, age, sex, the diabetic, and cirrhotic status of the patients, and the follow-up durations. Moreover, consistent results were obtained in studies with and without adjustment of antiviral treatment and statin use."},{"id":"source_22","type":"source","study":"Daily low dose aspirin halves incident type 2 diabetes in elderly subjects with prediabetes: a five-year longitudinal cohort study in a real-word population","year":2025,"doi":"10.1186/s12933-025-02802-9","url":"https://doi.org/10.1186/s12933-025-02802-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Lembo 2025","excerpt":"BACKGROUND: Prediabetes represents the final stage on the glycemic spectrum before the onset of type 2 diabetes mellitus (T2DM), and delaying its progression offers a unique opportunity to address the growing T2DM epidemic. METHODS: In this longitudinal cohort study, we investigated the effect of daily low-dose aspirin on the development of T2DM in individuals with prediabetes residing in Naples, Italy, who were followed by their primary care physicians between 2018 and 2022. Outcomes in the aspirin-treated group were compared with those in a control group not receiving aspirin, using data from the same database. Propensity score matching was employed to ensure comparability of covariates at baseline. RESULTS: The primary outcome was the onset of T2DM, defined as a new diagnosis accompanied by antidiabetic prescriptions lasting more than 30 days. Gastrointestinal bleeding was assessed as the safety endpoint. Over the follow-up period, 488 new cases of T2DM were documented (15.6% of the total population), with 174 cases occurring in the aspirin group (22.3 per 1000 person-years) and 314 in the non-aspirin group (40."},{"id":"source_23","type":"source","study":"Aspirin use is associated with attenuated risk of severe acute kidney injury in septic patients: a dual-center retrospective analysis from MIMIC-IV and eICU cohorts","year":2025,"doi":"10.1080/0886022X.2025.2568650","url":"https://doi.org/10.1080/0886022X.2025.2568650","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Luo 2025","excerpt":"Sepsis is a systemic inflammatory response syndrome caused by infection, and sepsis-associated acute kidney injury (AKI) markedly increases mortality. Although aspirin's anti-inflammatory properties show therapeutic promise in sepsis, its specific renal protective effects in septic patients remain underexplored. This study investigated the association between aspirin exposure and severe acute kidney injury in septic patients using two databases: MIMIC-IV (73,181 ICU stays, 2008-2022), and eICU (200,859 ICU stays, 2014-2015). Among 45,562 septic patients, cohorts were stratified by aspirin exposure, and outcome variables were compared using multiple statistical adjustment methods including multivariable regression and propensity score analysis. The primary outcome was severe AKI incidence, with secondary outcomes including overall AKI, continuous renal replacement therapy (CRRT), and mortality. Our study suggests that aspirin exposure was associated with significantly lower severe AKI incidence in both databases (adjusted OR 0.35 in MIMIC-IV; 0.84 in eICU), representing risk reductions ranging from 16% to 65%."},{"id":"source_24","type":"source","study":"Analysis of prenatal medication use and placental epigenetic gestational age in extremely low gestational age newborns (ELGANs) highlight relationships to aspirin use during pregnancy","year":2025,"doi":"10.1186/s13148-025-01988-9","url":"https://doi.org/10.1186/s13148-025-01988-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Huff 2025","excerpt":"BACKGROUND: Several maternal exposures such as acetaminophen during pregnancy have been previously associated with altered placental CpG methylation. Epigenetic gestational age measures biological aging using DNA methylation from gestational tissues such as placenta and cord blood. We hypothesize that placental epigenetic gestational age (eGA) could serve as a biomarker for maternal exposures or pathological processes that influence placental development. To investigate relationships between maternal exposures and placental eGA, we evaluated prenatal medication use (antibiotics, acetaminophen, aspirin, and ibuprofen) in relation to placental epigenetic gestational age acceleration (eGAA) using the Robust Placental Clock (RPC). We also examined associations between these four exposures and the methylation levels of the 558 individual CpGs comprising the RPC. Using data from the Extremely Low Gestational Age Newborns (ELGAN) study (N = 408), we ran linear mixed-effects regression models that accounted for multiple births to the same mother. We further stratified by infant sex assigned at birth to assess effect measure modification."},{"id":"source_25","type":"source","study":"Aspirin might reduce the incidence of breast cancer","year":2020,"doi":"10.1097/MD.0000000000021917","url":"https://doi.org/10.1097/MD.0000000000021917","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Cao 2020","excerpt":"BACKGROUND: Many epidemiologic studies were performed to clarify the protective effect of regular aspirin use on breast cancer risks, but the results remain inconsistent. Here, we conducted an updated meta-analysis of 38 studies to quantitatively assess the association of regular aspirin use with risk of breast cancer. METHOD: We performed a bibliographic database search in PubMed, Embase, Web of Science, Cochrane library, Scopus, and Google Scholar from January 1939 to December 2019. Relative risk (RR) estimates were extracted from eligible case-control and cohort studies and pooled using a random effects model. Subgroup analysis was conducted based on study design, aspirin exposure assessment, hormone receptor status, menopausal status, cancer stage as well as aspirin use duration or frequency. Furthermore, sensitivity and publication bias analyses were performed. RESULTS: Thirty eight studies of 1,926,742 participants involving 97,099 breast cancer cases contributed to this meta-analysis. Compared with nonusers, the aspirin users had a reduced risk of breast cancer (RR = 0.91, 95% confidence interval [CI]: 0.87-0.95, P value of significance [Psig] < ."},{"id":"source_26","type":"source","study":"Association Between Aspirin Usage and Age-Related Macular Degeneration: An Updated Systematic Review and Meta-analysis","year":2022,"doi":"10.3389/fphar.2022.824745","url":"https://doi.org/10.3389/fphar.2022.824745","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Yan 2022","excerpt":"Purpose: To investigate the association between long-term use of aspirin and age-related macular degeneration (AMD). Methods: An updated systematic literature search was conducted in PubMed, Medline, Cochrane Library, and embase from conception to February 26, 2021, without any language restriction. All studies that evaluated the relationship between long-term aspirin use and AMD were included. Results: In the current study, 16 articles were pooled. Overall, no significant association was observed (estimate ratio = 1.108, 95% confidence interval (CI): 0.886-1.385). When the subgroups were evaluated according to various standards, aspirin use was significantly correlated with AMD in studies with volunteer participants (estimate ratio = 0.899, 95% CI: 0.830-0.974, p < 0.01), studies followed up for >10 years (estimate ratio = 2.206, 95% CI: 2.124-2.292, p < 0.01), duration of aspirin use >10 years (estimate ratio = 2.323, 95% CI: 2.234-2.416, p < 0.01), and cohort studies (estimate ratio = 1.961, 95% CI: 1.893-2.032, p < 0.01)."},{"id":"source_27","type":"source","study":"Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis","year":2022,"doi":"10.1016/j.ahjo.2022.100191","url":"https://doi.org/10.1016/j.ahjo.2022.100191","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Srinivasan 2022","excerpt":"Thromboembolism is a major cause of death in patients who suffer from COVID-19. Studies examining the effects of aspirin (ASA) on mortality relating to this phenomenon have showed conflicting results with varying degrees and certainties of evidence. We performed an aggregate data meta-analysis of fourteen studies encompassing 164,539 COVID-19 patients, which showed a reduced risk of in-hospital mortality associated with ASA use in eight studies that reported risk ratios (RR 0.90; 95 % CI 0.82-0.98; I 2 = 27.33 %, P = 0.01), six studies that reported hazard ratios (HR 0.56; 95 % CI 0.41-0.76, P ≤ 0.01; I 2 = 85.92 %) and pooled effect size (0.71; 95 % CI 0.59-0.85, P = 0.00, I 2 = 91.51 %). The objective of this study is to report the association between low dose ASA and a reduced risk of in-hospital mortality in patients with COVID-19."},{"id":"source_28","type":"source","study":"Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis","year":2022,"doi":"10.3389/fphar.2022.989903","url":"https://doi.org/10.3389/fphar.2022.989903","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Su 2022","excerpt":"Introduction: Whether aspirin or other antiplatelet drugs can reduce mortality among patients with coronavirus disease (COVID-19) remains controversial. Methods: We identified randomized controlled trials, prospective cohort studies, and retrospective studies on associations between aspirin or other antiplatelet drug use and all-cause mortality among patients with COVID-19 in the PubMed database between March 2019 and September 2021. Newcastle-Ottawa Scale and Cochrane Risk of Bias Assessment Tool were used to assess the risk of bias. The I 2 statistic was used to assess inconsistency among trial results. The summary risk ratio (RR) and odds ratio (OR) were obtained through the meta-analysis. Results: The 34 included studies comprised three randomized controlled trials, 27 retrospective studies, and 4 prospective cohort studies. The retrospective and prospective cohort studies showed low-to-moderate risks of bias per the Newcastle-Ottawa Scale score, while the randomized controlled trials showed low-to-high risks of bias per the Cochrane Risk of Bias Assessment Tool."},{"id":"source_29","type":"source","study":"Effect of aspirin use on conversion risk from mild cognitive impairment to Alzheimer’s disease","year":2025,"doi":"10.3389/fnagi.2025.1603892","url":"https://doi.org/10.3389/fnagi.2025.1603892","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Choi 2025","excerpt":"BACKGROUND: The potential effect of the antiplatelet and anti-inflammatory properties of aspirin on Alzheimer's disease development, especially its role in the progression from mild cognitive impairment to Alzheimer's disease dementia, remains controversial. To evaluate the association between aspirin, use and the risk of conversion to Alzheimer's disease dementia among individuals diagnosed with mild cognitive impairment. METHODS: In this retrospective population-based cohort study, we used the Korean National Health Insurance Service database to collect data on patients with mild cognitive impairment enrolled between 2013 and 2016 and followed up until 2021. In total, 508,107 patients initially diagnosed with mild cognitive impairment (192,538 with aspirin prescriptions and 315,569 without aspirin prescriptions) were enrolled. Aspirin use was assessed by extracting information from the Korean National Health Insurance Service database using aspirin prescription codes. The primary outcome was newly diagnosed Alzheimer's disease dementia."},{"id":"source_30","type":"source","study":"Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study","year":2025,"doi":"10.1080/07853890.2025.2573146","url":"https://doi.org/10.1080/07853890.2025.2573146","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Huang 2025","excerpt":"BACKGROUND: The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, is increasing. While daily aspirin use has been associated with reduced hepatocellular carcinoma (HCC) risk in NAFLD, its impact on mortality and liver-related outcomes in MASLD remains unclear. METHODS: This retrospective, multi-institutional cohort study included 48,722 MASLD patients from 2008 to 2020, divided into aspirin users and non-users. Exclusion criteria included significant cardiac disease unrelated to aspirin, alcoholic liver disease, incomplete follow-up, and concomitant use of other antiplatelet therapies. Propensity score matching (PSM) was performed to balance baseline characteristics, including demographics, cirrhosis status, ALT levels, cardiovascular conditions, and concurrent medications. RESULTS: After PSM, 2003 patients were included in each cohort. Aspirin users had a mean duration of use of 4.59 ± 3.97 years, with 97% on a daily dose of 75-100 mg."},{"id":"source_31","type":"source","study":"Inappropriate Use of Aspirin in Real-Life Cardiology Practice: Results from the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) Study","year":2021,"doi":"10.5152/balkanmedj.2021.21143","url":"https://doi.org/10.5152/balkanmedj.2021.21143","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Celik 2021","excerpt":"BACKGROUND: Indications and appropriateness of aspirin use have not been well investigated in Turkey. AIMS: To investigate the prescription patterns and appropriateness of aspirin in a real-world clinical setting. STUDY DESIGN: Cross-sectional study. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) is a cross-sectional and multicenter study that included 5007 consecutive patients aged 18 or over who presented to 30 different cardiology outpatient clinics from 14 cities throughout Turkey. Only patients using aspirin (80-325 mg) were included. The study population was divided into 2 groups regarding the use of aspirin: primary prevention (PP) group and secondary prevention (SP) group. The indication of aspirin use was evaluated following the 2016 European Society of Cardiology (ESC) and the 2016 United States Preventative Services Task Force (USPTF) guidelines in the PP group. RESULTS: A total of 5007 patients (mean age 62.15 ± 11.05, 39% female) were enrolled. The PP group included 1132 (22.6%) patients, and the SP group included 3875 (77.4%) patients."},{"id":"source_32","type":"source","study":"Regular aspirin use among a sample of American Indians/Alaskan Natives in the Upper Midwest region of the United States","year":2023,"doi":"10.1016/j.pmedr.2023.102571","url":"https://doi.org/10.1016/j.pmedr.2023.102571","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Alabsi 2023","excerpt":"Despite high prevalence of cardiovascular disease (CVD) and CVD risk factors among American Indian or Alaska Native adults (AI/AN), there is little information on aspirin use in this population. This survey-based study seeks to understand prevalence of aspirin use in a sample of AI/AN adults in the Upper Midwestern United States. In-person and telephone based surveys were conducted querying self-reported CVD and CVD risk factors, aspirin use, and aspirin related discussion with clinicians. A total of 237 AI/AN participants were included: mean age (SD) was 60.8 (8.4) years; 143 (60 %) were women; 59 (25 %) reported CVD history. CVD risk factors were common particularly smoking (37 %) and diabetes (37 %). Aspirin use was much higher among those with CVD (secondary prevention, 76 %) than those without (primary prevention, 33 %). Primary prevention aspirin use was significantly associated with age and all CVD risk factors in unadjusted analyses. After adjustment for demographics and CVD risk factors, only age (aRR 1.13 per 5 years, 95 % CI 1.02, 1.25) and diabetes (aRR 2.44, 95 % CI 1.52, 3.92) remained significantly associated with aspirin."},{"id":"source_33","type":"source","study":"Effect of pre-ICU aspirin use on neuroinflammation and outcomes in patients with sepsis-associated encephalopathy","year":2026,"doi":"10.3389/fneur.2026.1708039","url":"https://doi.org/10.3389/fneur.2026.1708039","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Xu 2026","excerpt":"OBJECTIVE: To investigate the effect of pre-ICU aspirin use on neuroinflammation and prognosis in sepsis-associated encephalopathy (SAE) patients. METHODS: Clinical data of SAE patients admitted to our ICU (Mar 2022-Feb 2025) were retrospectively analyzed. Patients were grouped based on pre-admission aspirin use: exposed ( n = 45) and non-exposed ( n = 68). After 1:1 propensity score matching (age, infection source; caliper = 0.2), 42 matched pairs were compared. Cerebral hemodynamics (Vm, Vd, and Vs), coagulation function (PLT, TT, PT, and APTT), neuroinflammation markers (IL-6, TNF-α, and S100β), Glasgow Coma Scale (GCS), Sequential Organ Failure Assessment (SOFA) scores (admission, days 1, 3, and 5), ICU length of stay, adverse events, 28- and 60-day mortality were analyzed using appropriate statistical tests (t-test, χ 2 test; P < 0.05 significant). RESULTS: The exposed group had higher Vm, Vd, and Vs at all time points ( P < 0.05). IL-6, TNF-α, and S100β levels were lower in the exposed group ( P < 0.05). GCS scores were higher in the exposed group on days 3 and 5 ( P < 0.05). Adverse event incidence, ICU stay, and 28-day mortality did not differ significantly ( P < 0.05)."},{"id":"source_34","type":"source","study":"Promoting Aspirin Use for Cardiovascular Disease Prevention Among an Adult Internet-Using Population: A Pilot Study","year":2021,"doi":"10.3389/fpubh.2021.500296","url":"https://doi.org/10.3389/fpubh.2021.500296","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Oldenburg 2021","excerpt":"Cardiovascular disease prevention strategies include aspirin use as a preventive measure. The internet can be used to raise public awareness, promote healthy lifestyles, and improve disease management. This pilot study describes the feasibility of an educational website to recruit and follow adult internet users to examine whether they talked to their physician about aspirin and initiated aspirin use. As part of a statewide intervention promoting an aspirin regimen to prevent heart attacks and strokes in Minnesota, visitors to the website were encouraged to complete an aspirin candidacy tool. Between October, 2015 and February, 2016, men 45-79 and women 55-79 who identified as aspirin candidates were invited to participate in a 6-month study involving four, 5 min online surveys to examine physician discussions about aspirin, aspirin use, and mobile technology use. During the 5-month recruitment period, 234 adults enrolled in the study. Of the 174 who completed the baseline survey and at least one follow-up survey, 74 (43.5%) did not use aspirin at baseline. During follow-up, 12 (16.2%) talked to their doctor about aspirin and 31 (41.8%) initiated aspirin use."},{"id":"source_35","type":"source","study":"Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis","year":2021,"doi":"10.3389/fendo.2021.741374","url":"https://doi.org/10.3389/fendo.2021.741374","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Ma 2021a","excerpt":"PURPOSE: A meta-analysis was conducted to assess the benefits and risks of aspirin for the primary prevention of cardiovascular disease and all-cause mortality events in adults with diabetes. METHODS: An extensive and systematic search was conducted in MEDLINE (via PubMed), Cinahl (via Ebsco), Scopus, and Web of Sciences from 1988 to December 2020. A detailed literature search was conducted using aspirin, cardiovascular disease (CVD), diabetes, and efficacy to identify trials of patients with diabetes who received aspirin for primary prevention of CVD. Demographic details with the primary outcome of events and bleeding outcomes were analyzed. The Cochrane Collaboration's risk of bias tool was used to assess the methodological quality of the included studies. Random-effects meta-analysis was used to calculate the pooled odds ratio for outcomes of cardiovascular events, death, and adverse events. FINDINGS: A total of 8 studies were included with 32,024 patients with diabetes; 16,001 allocated to aspirin, and 16,023 allocated to the control group."},{"id":"source_36","type":"source","study":"Association of a Community Population and Clinic Education Intervention Program With Guideline-Based Aspirin Use for Primary Prevention of Cardiovascular Disease","year":2022,"doi":"10.1001/jamanetworkopen.2022.11107","url":"https://doi.org/10.1001/jamanetworkopen.2022.11107","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Luepker 2022","excerpt":"IMPORTANCE: Low-dose aspirin is used for primary prevention of cardiovascular disease in approximately one-third of the US adult population. Overuse and underuse are common and not concordant with guidelines. OBJECTIVE: To test a community and clinic education intervention to improve guideline-based aspirin use for the primary prevention of cardiovascular disease. DESIGN, SETTING, AND PARTICIPANTS: The Ask About Aspirin project was a nonrandomized controlled trial conducted from, July 1, 2015, to March 31, 2020, using professional education, traditional media, and digital media to improve guideline-based aspirin use. The adult population (aged 45-79 years for men and 55-79 years for women) and primary care clinics in Minnesota were the education targets. The 4 adjacent states were controls. INTERVENTIONS: The statewide campaign distributed billboards, newspaper articles and other print material, and radio announcements. An Ask About Aspirin website was heavily promoted. Primary care clinics identified appropriate aspirin candidates, and clinicians received continuing education about aspirin. MAIN OUTCOMES AND MEASURES: Guideline-based aspirin use by the target population."},{"id":"source_37","type":"source","study":"Association Between Prior Aspirin Use and Acute Respiratory Distress Syndrome Incidence in At-Risk Patients: A Systematic Review and Meta-Analysis","year":2020,"doi":"10.3389/fphar.2020.00738","url":"https://doi.org/10.3389/fphar.2020.00738","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Liang 2020","excerpt":"BACKGROUND: Recent studies have shown that prior antiplatelet drug use could ameliorate the risk and mortality of acute respiratory distress syndrome (ARDS). However, the connection between prior acetylsalicylic acid (aspirin) use and the risk of ARDS is unknown. Our primary objective was to perform a meta-analysis on the currently available studies to assess the association between aspirin use prior to ARDS onset and ARDS incidence in at-risk patients. METHODS: Two investigators separately searched four research databases: MEDLINE, EMBASE, Cochrane Library, and Web of Science for relevant articles from the earliest available data through to July 14, 2019. In this paper, we performed a meta-analysis of the fixed effects model using the inverse variance-weighted average method to calculate the pooled odds ratios (ORs) and 95% confidence intervals (CIs). The primary outcome was risk of ARDS, and the secondary outcome was the hospital mortality of at-risk patients. RESULTS: This article included seven studies altogether, enrolling 6,764 at-risk patients."},{"id":"source_38","type":"source","study":"Continuous aspirin treatment improves cardiovascular events and all-cause mortality in hemodialysis patients with peripheral artery disease","year":2024,"doi":"10.1080/0886022X.2024.2380754","url":"https://doi.org/10.1080/0886022X.2024.2380754","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Wu 2024","excerpt":"BACKGROUND: Hemodialysis (HD) patients with peripheral arterial disease (PAD) are at heightened risk of adverse vascular events, and aspirin positively affects those outcomes. We aimed to investigate the association between different patterns of aspirin use and clinical vascular events in chronic HD patients with PAD. METHODS: This retrospective nationwide cohort study enrolled 758 chronic HD patients who had been diagnosed with PAD between January 1, 2008, and December 31, 2012, and followed up until the end of 2020. Patients were divided into three groups according to medication possession ratio (MPR) and continued use of aspirin (i.e., low MPR, high MPR but discontinuous prescription, and high MPR and continuous prescription). Percutaneous transluminal angioplasty (PTA), surgical bypass, lower leg amputation, cardiovascular events, cerebrovascular events, and all-cause mortality were evaluated. RESULTS: High MPR and continuous aspirin use had the lowest incidence of all-cause mortality and cardiovascular events compared with the two other groups, and it was significantly associated with low risk of PTA, surgical bypass, cardiovascular events, and all-cause mortality (aHR: 0."},{"id":"source_39","type":"source","study":"Impact of prior aspirin use on left ventricular function in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: An echocardiographic evaluation","year":2024,"doi":"10.34172/jcvtr.33184","url":"https://doi.org/10.34172/jcvtr.33184","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Yosefzadeh 2024","excerpt":"INTRODUCTION: Previous studies have investigated the potential influence of prior aspirin use on cardiac function in patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PPCI). However, the results from these studies have been conflicting. This study aimed to investigate whether prior aspirin use affects left ventricular (LV) function in these patients using echocardiography. METHODS: The study included 260 consecutive STEMI patients, who were divided into two groups based on the presence or absence of prior aspirin use. Echocardiographic parameters, such as maximal left atrial (LA) size, LV ejection fraction (LVEF), early diastolic velocity (e'), E/A ratio, and E/e' ratio, were assessed within 72 hours of admission. RESULTS: Aspirin users had an older age compared to non-users, as well as lower body mass index and renal function. They also had a greater history of hypertension and were more likely to be taking statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and calcium channel blockers."},{"id":"source_40","type":"source","study":"Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta‐analysis","year":2022,"doi":"10.1111/ene.15433","url":"https://doi.org/10.1111/ene.15433","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Clarke 2022","excerpt":"BACKGROUND AND PURPOSE: The purpose was to determine whether prior use of antiplatelet therapy modifies the effect of dual antiplatelet therapy in patients with acute minor ischaemic stroke or transient ischaemic attack. METHODS: A systematic review and meta-analysis of randomized controlled trials was performed comparing dual antiplatelet therapy to aspirin that reported subgroup analysis by prior antiplatelet use, adhering to the Cochrane Collaboration Guidelines. A fixed-effects meta-analysis was used to estimate a pooled treatment effect overall in subgroups with prior aspirin therapy and without prior aspirin therapy. Difference in treatment effect was assessed by testing p for interaction. The primary outcome measure was recurrent vascular events. RESULTS: Three eligible randomized controlled trials were identified, including 4831 participants with pre-existing antiplatelet use and 16,236 participants without pre-existing aspirin use. Recurrent vascular events occurred in 7.2% (95% confidence interval [CI] 4.3-10) of those without pre-existing aspirin use versus 7.3% (95% CI 4.1-10) of those receiving prior aspirin therapy."},{"id":"source_41","type":"source","study":"The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis","year":2024,"doi":"10.1186/s40246-024-00699-1","url":"https://doi.org/10.1186/s40246-024-00699-1","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Li 2024","excerpt":"BACKGROUND: Recently, extensive research has been conducted on the relationship between aspirin gene polymorphisms and aspirin resistance (AR) in patients with ischemic diseases. Among the numerous candidate genes, it remains unclear which ones are significantly associated with AR and could potentially serve as potential biomarkers for genetic testing before aspirin use. METHODS: Eligible articles were searched in PubMed, Embase, Cochrane Library, WanFang, CNKI and Sinomed. A cohort study examining the efficacy of aspirin in secondary prevention for patients with ischemic diseases, along with a discussion on genetic polymorphisms and their association with AR, has been included. The Newcastle-Ottawa Scale for assessing the quality of included studies. Odds ratios (OR) with 95% confidence intervals (CI) were used as measures of effect. Subgroup analyses were conducted based on different genotypes with the same genetic polymorphisms, different research regions and types of ischemic diseases. RESULTS: From 75 eligible articles, 94 candidate gene polymorphisms were analyzed. In the overall analysis, 25 genes were subjected to meta-analysis and 69 genes were systematically described."},{"id":"source_42","type":"source","study":"Safety of Continuing Aspirin Use in Cervical Laminoplasty: A Propensity Score-Matched Analysis","year":2022,"doi":"10.22603/ssrr.2022-0163","url":"https://doi.org/10.22603/ssrr.2022-0163","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Wong 2022","excerpt":"INTRODUCTION: Aspirin is commonly used for the primary and secondary prevention of cardiovascular disease and stroke. Controversy exists concerning whether and when is the optimal time to stop aspirin before spinal surgery. Previous studies on this topic mainly focused on patients who received thoracolumbar spine surgeries. There are only a few literatures concerning the safety of aspirin use in cervical spine surgery patients. METHODS: This pilot study recruited patients who received cervical laminoplasty from January 2010 to December 2021. The operation time, intraoperative blood loss, and postoperative complications of the patients who had taken aspirin during the perioperative period were compared with age, sex, and comorbidity-matched control patients. Propensity score matching was utilized in the selection of control to minimize bias. RESULTS: Twenty-one patients who have received cervical laminoplasty while taking aspirin during the perioperative period were included. The control group included 21 age, sex, and comorbidity-matched patients who have not taken aspirin."},{"id":"source_43","type":"source","study":"Aspirin improves short and long term survival outcomes of patients with sepsis associated encephalopathy","year":2025,"doi":"10.1038/s41598-025-08075-2","url":"https://doi.org/10.1038/s41598-025-08075-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Gong 2025","excerpt":"Sepsis-associated encephalopathy (SAE) is a common complication of sepsis, characterized by altered mental status and contributing to higher mortality. Aspirin, an antiplatelet agent with anti-inflammatory properties, may improve outcomes in patients with SAE. This study aims to evaluate the effect of aspirin on the prognosis of patients with SAE. A retrospective cohort study using the Medical Information Mart for Intensive Care IV (MIMIC-IV 2.2) database included 5840 patients with SAE: aspirin group (n = 3378) and non-aspirin group (n = 2462). Propensity score matching (PSM) at a 1:1 ratio resulted in 1770 matched pairs. The primary outcomes were 28-day, 90-day, 365-day, and 1095-day survival rates. Secondary outcomes included ICU length of stay, incidence of gastrointestinal bleeding, and thrombocytopenia. After PSM, baseline characteristics were balanced. The aspirin group had significantly higher survival rates at all time points (p < 0.05) compared to the non-aspirin group. ICU length of stay and incidence of gastrointestinal bleeding and thrombocytopenia were not significantly different between groups after matching."},{"id":"source_44","type":"source","study":"Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults.","year":2021,"doi":"10.1093/geroni/igab046.2339","url":"https://doi.org/10.1093/geroni/igab046.2339","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Orchard 2021","excerpt":"For participants with controlled diabetes, there was a significant reduction in cancer mortality in metformin users compared to nonusers (Adjusted [Adj] HR=0.24, 95%CI=0.07, 0.80), but not for cancer incidence (Adj HR=0.61, 95%CI=0.29, 1.27). For participants with uncontrolled diabetes, there was no significant difference in cancer incidence (Adj HR=0.95, 95%CI=0.66, 1.38) or mortality (Adj HR=1.18, 95%CI=0.62, 2.26) between metformin and non-metformin users."},{"id":"source_45","type":"source","study":"Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019.","year":2021,"doi":"10.1016/j.clbc.2021.02.005","url":"https://doi.org/10.1016/j.clbc.2021.02.005","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Ma 2021b","excerpt":"BACKGROUND: Some evidence shows that aspirin can reduce the morbidity and mortality of different cancers, including breast cancer. Aspirin has become a new focus of cancer prevention and treatment research at present, however, clinical studies found conflicting conclusions of its anticancer characteristics. MATERIALS AND METHODS: A systematic literature search was performed in 8 electronic databases. The pooled relative risk (RR) with 95% confidence interval (CI) was calculated using the random effects model to estimate the effect of aspirin on breast cancer. RESULTS: Forty-two published articles with 99,769 patients were identified. The meta-analysis showed a significant decrease in breast cancer risk with aspirin use (RR, 0.92; 95% CI, 0.89-0.96; I 2 = 72%). Aspirin use decreased the risk of hormone receptor-positive tumors (estrogen receptor [ER]-positive RR, 0.89; 95% CI, 0.82-0.97; I 2 =54%; progesterone receptor [PR]-positive RR, 0.86; 95% CI, 0.78-0.95; I 2 =32%; ER- and PR-positive RR, 0.92; 95% CI, 0.85-1.00; I 2 =45%) and reduced the risk of breast cancer in postmenopausal women (RR, 0.92; 95% CI, 0.86-0.98; I 2 =59%)."},{"id":"source_46","type":"source","study":"Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis.","year":2021,"doi":"10.1016/j.clinre.2020.09.006","url":"https://doi.org/10.1016/j.clinre.2020.09.006","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Li 2021c","excerpt":"BACKGROUND: Aspirin use has been suggested to reduce cancer risk. However, previous studies showed inconsistent results as for the association between aspirin use and mortality in patients with hepatocellular carcinoma (HCC). The aim of the study was to evaluate the influence of aspirin use on clinical outcomes of patients with HCC in a meta-analysis. MATERIALS: Studies were obtained via systematic search of PubMed, Cochrane's Library, and Embase databases. A random-effect model, which incorporated the potential heterogeneity, was used to pool the results. RESULTS: Six retrospective cohort studies including 18,855 HCC patients that underwent liver resection or transarterial chemoembolization were included. Pooled results showed that compared to the non-users, aspirin users of HCC had significantly reduced risk of HCC recurrence (risk ratio [RR]: 0.74, 95% confidence interval [CI]: 0.59-0.93, p = 0.01; I 2 = 34%) and all-cause mortality (RR: 0.59, 95% CI: 0.47-0.73, p < 0.001; I 2 = 0%) after controlling of potential confounding factors. In addition, pooled results showed that aspirin use was not associated with a significantly increased risk of major bleeding events (RR: 1."},{"id":"source_47","type":"source","study":"Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019.","year":2021,"doi":"10.1213/ane.0000000000005292","url":"https://doi.org/10.1213/ane.0000000000005292","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Chow 2021","excerpt":"BACKGROUND: Coronavirus disease-2019 (COVID-19) is associated with hypercoagulability and increased thrombotic risk in critically ill patients. To our knowledge, no studies have evaluated whether aspirin use is associated with reduced risk of mechanical ventilation, intensive care unit (ICU) admission, and in-hospital mortality. METHODS: A retrospective, observational cohort study of adult patients admitted with COVID-19 to multiple hospitals in the United States between March 2020 and July 2020 was performed. The primary outcome was the need for mechanical ventilation. Secondary outcomes were ICU admission and in-hospital mortality. Adjusted hazard ratios (HRs) for study outcomes were calculated using Cox-proportional hazards models after adjustment for the effects of demographics and comorbid conditions. RESULTS: Four hundred twelve patients were included in the study. Three hundred fourteen patients (76.3%) did not receive aspirin, while 98 patients (23.7%) received aspirin within 24 hours of admission or 7 days before admission. Aspirin use had a crude association with less mechanical ventilation (35.7% aspirin versus 48.4% nonaspirin, P = .03) and ICU admission (38."},{"id":"source_48","type":"source","study":"Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes","year":2022,"doi":"10.1101/2022.08.03.22278392","url":"https://doi.org/10.1101/2022.08.03.22278392","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Abul 2022","excerpt":"The primary outcome was mortality at 30 and 56 days post positive test and hospitalization. Aspirin use was independently associated with a reduced risk of 30 days of mortality (adjusted HR, 0.60, 95% CI, 0.40-0.90) and 56 days of mortality (adjusted HR, 0.67, 95% CI, 0.47-0.95) Conclusion Chronic low dose aspirin use for primary or secondary prevention of cardiovascular events is associated with lower COVID-19 mortality."},{"id":"source_49","type":"source","study":"Shared decision making and patient reported outcomes among adults with atherosclerotic cardiovascular disease, medical expenditure panel survey 2006–2015","year":2021,"doi":"10.1016/j.ajpc.2021.100281","url":"https://doi.org/10.1016/j.ajpc.2021.100281","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Okunrintemi 2021","excerpt":"IMPORTANCE: Shared decision-making (SDM), one of the pillars of patient centered care is strongly encouraged and has been incorporated into the management of atherosclerotic cardiovascular disease (ASCVD) but the expansion of its use has been limited. OBJECTIVE: To determine the association of SDM on patient-reported health status, measures of quality of care, healthcare resource utilization, and healthcare spending among US adults with ASCVD. METHOD: This is a retrospective cohort study in an ambulatory setting, utilizing the Medical Expenditure Panel Survey (MEPS) 2006-2015. Analysis completed in December 2020. Participants included were adults 18 years and over with a diagnosis of ASCVD. We used the average weighted response to self-administered questionnaire evaluating shared-decision-making process as the exposure variable in the regression model. Outcome measures included inpatient hospitalizations, Emergency Department (ED) visits, statin and aspirin use, self-perception of health, and healthcare expenditure. RESULTS: When compared with individuals reporting poor SDM, those with optimal SDM were more likely to report statin and aspirin use [statin use, Odds Ratio (OR) 1."},{"id":"source_50","type":"source","study":"Low-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort studies.","year":2021,"doi":"10.1093/pubmed/fdz114","url":"https://doi.org/10.1093/pubmed/fdz114","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Wang 2021b","excerpt":"BACKGROUND: Considering the increased risk of bleeding caused by aspirin, and the observed benefit in all-cause mortality may be due to an improvement in cardiovascular-related mortality. We carried out this meta-analysis to estimate the association of low-dose aspirin use and risk of cancer-specific mortality. METHODS: We searched the PubMed and China National Knowledge Infrastructure (CNKI) databases for all articles within a range of published years from 1980 to 2018. RESULTS: Finally, 13 published cohort studies with 65 768 patients were available for estimating overall risk of cancer-specific mortality associating with post-diagnosis low-dose aspirin use, and 4 cohort studies were available for pre-diagnosis low-dose aspirin use with 16 654 patients. Overall, statistical evidence of significantly decreased cancer-specific mortality was found to be associated with post-diagnosis low-dose aspirin use (OR = 0.84, 95% CI = 0.75-0.93), but not with pre-diagnosis low-dose aspirin use."},{"id":"source_51","type":"source","study":"Inflammation, Frailty, and Aspirin Use in the Physicians' Health Study: A Pilot Study.","year":2024,"doi":"10.14283/jfa.2024.37","url":"https://doi.org/10.14283/jfa.2024.37","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Gewurz 2024","excerpt":"Whether anti-inflammatory medications such as aspirin can lower the risk of frailty is an active area of investigation. In previous studies, we reported that regular aspirin use started in midlife was associated with a lower risk of frailty at older age. We therefore sought to further examine the relationship between inflammatory biomarkers, frailty and aspirin use in a pilot nested case-control study of 300 participants aged ≥60 years with available data to calculate a frailty index from the Physicians' Health Study, a completed randomized trial of aspirin that began in 1982. We selected 150 individuals who were frail (frailty index >0.2) and 150 who were not frail (frailty index <0.1). We then matched 29 low users of aspirin (≤60 days/year) 3:1 to 87 regular users of aspirin (>60 days/year). After matching on age, smoking status, history of diabetes and CVD, there was no significant association between aspirin use and level of frailty among those with elevated inflammatory biomarkers (all p>0.05). In this pilot study we did not find evidence of a mediation effect of CRP, TNFR-2 or IL-6 on the association between aspirin and frailty."},{"id":"source_52","type":"source","study":"Aspirin use and pancreatic cancer risk","year":2019,"doi":"10.1097/MD.0000000000018033","url":"https://doi.org/10.1097/MD.0000000000018033","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Sun 2019","excerpt":"OBJECTIVES: Although there is evidence that aspirin might be able to prevent pancreatic cancer, the findings have been inconsistent. In this paper, we conducted a meta-analysis of observational studies to examine the relationship between aspirin use and the risk of pancreatic cancer. METHODS: We identified potential studies by searching the MEDLINE, EMBASE, and Wangfang (Chinese database) database (from 1967 to March 2017) and by reviewing the bibliography of relevant publications. Random effects model was used to calculate odds ratio (OR) and 95% confidence interval. The Cochran Q statistic (significance level at P < .1) was used to assess heterogeneity in this study. The author adopted weighted regression method of Egger to assessed publication bias. RESULTS: A total of 12 studies involving 4748 pancreatic cancer cases, were included in the meta-analysis. The study reflected that there was no signification association between aspirin use and mortality risk of pancreatic cancer. Aspirin use might reduce the incidence of pancreatic cancer."},{"id":"source_53","type":"source","study":"Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials","year":2019,"doi":"10.1186/s12933-019-0875-4","url":"https://doi.org/10.1186/s12933-019-0875-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Seidu 2019","excerpt":"BACKGROUND: The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CVD) in diabetes remains uncertain. To evaluate the efficacy and safety of aspirin for the primary prevention of cardiovascular outcomes and all-cause mortality events in people with diabetes, we conducted an updated meta-analysis of published randomised controlled trials (RCTs) and a pooled analysis of individual participant data (IPD) from three trials. METHODS: Randomised controlled trials of aspirin compared with placebo (or no treatment) in participants with diabetes with no known CVD were identified from MEDLINE, Embase, Cochrane Library, and manual search of bibliographies to January 2019. Relative risks with 95% confidence intervals were used as the summary measures of associations. RESULTS: We included 12 RCTs based on 34,227 participants with a median treatment duration of 5.0 years. Comparing aspirin use with no aspirin, there was a significant reduction in risk of major adverse cardiovascular events (MACE)0.89 (0.83-0.95), with a number needed to treat (NNT)of 95 (95% CI 61 to 208) to prevent one MACE over 5 years average follow-up."},{"id":"source_54","type":"source","study":"Design and rationale for the ASSOS study: Appropriateness of aspirin use in medical outpatients a multicenter and observational study","year":2018,"doi":"10.14744/AnatolJCardiol.2018.47587","url":"https://doi.org/10.14744/AnatolJCardiol.2018.47587","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"protocol","cited_as":"Celik 2018","excerpt":"OBJECTIVE: The aim of this study was to describe the current status of aspirin use and the demographic characteristics of patients on aspirin for primary and secondary prevention of cardiovascular diseases. METHODS: The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) trial was a multicenter, cross-sectional, and observational study conducted in Turkey. The study was planned to include 5000 patients from 14 cities in Turkey. The data were collected at one visit, and the current clinical practice regarding aspirin use was evaluated (ClinicalTrials.gov number NCT03387384). RESULTS: The study enrolled all consecutive patients who were admitted to the outpatient cardiology clinics from March 2018 until June 2018. Patients should be at least 18 years old, have signed written informed consent, and on aspirin (80-325 mg) therapy within the last 30 days. Cardiologists from the hospital participates in the study. Patients were divided into 2 categories according to presence or absence of atherosclerotic cardiovascular disease, namely secondary prevention group and primary prevention group, respectively."},{"id":"source_55","type":"source","study":"Reduction of intracerebral hemorrhage in hemodialysis patients after reducing aspirin use: A quality-assurance observational study","year":2017,"doi":"10.1371/journal.pone.0185847","url":"https://doi.org/10.1371/journal.pone.0185847","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Aoun 2017","excerpt":"There is so far no international consensus concerning the prescription of antithrombotic agents in hemodialysis patients. It is not clear yet why they cause more bleeding in some patients and are beneficial in others. We therefore tried to find out what triggers bleeding in this population. This is an observational before-and-after study that included all patients undergoing hemodialysis in our center between 2005 and 2015. We divided the study into two phases: phase one (125 patients) where aspirin was used without restrictions and phase two (110 patients) where aspirin was avoided in severe hypertension and primary prevention. We aimed to assess the differential occurrence of intracerebral hemorrhage between the two phases and the cardiovascular mortality of patients whether on aspirin or not. Bleeding events occurred in 12.8% of patients in phase one and 13.6% in phase two (p = 0.85). Seven out of 125 patients (6%) in phase one experienced intracerebral hemorrhage and none in phase two. Intracerebral hemorrhage was significantly increased in those with the combination of aspirin and severe hypertension (p = 0.003)."}],"edges":[{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_1","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_2","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_3","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_4","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_5","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_6","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_7","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_8","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_9","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_10","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_11","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_12","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_13","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_14","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_15","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_16","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_17","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_18","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_19","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_20","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_21","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_22","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_23","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_24","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_25","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_26","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_27","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_28","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_29","type":"contains_claim"},{"from":"145fcccc-2360-4120-8674-34dd3e97ade7","to":"claim_30","type":"contains_claim"}],"screening":{"identified":55,"screened":55,"excluded":0,"included":55,"included_or_retained":55,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"55 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"145fcccc-2360-4120-8674-34dd3e97ade7","screening":{"identified":55,"screened":55,"excluded":0,"included":55,"included_or_retained":55,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"55 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Aspirin remains one of the most widely used medications globally, yet its effects beyond cardiovascular prophylaxis — including on cancer incidence and survival, infection-related mortality, and aging-relevant outcomes — remain actively debated as guidelines shift and observational cohorts proliferate. We conducted an AI-assisted structured evidence synthesis across 55 curated reference papers indexed for Aspirin, extracting effect estimates, confidence intervals, and p-values into an audit-trailed evidence table while preserving the design and directness annotations supplied by the original sources. For COVID-19, pooled analyses of hospitalized patients indicated that aspirin use was independently associated with reduced in-hospital mortality (P = 0.007), mechanical ventilation, and ICU admission, although a parallel meta-analysis limited to randomized controlled trials found no statistically significant effect on all-cause mortality. Safety signals include increased intracerebral hemorrhage when aspirin was combined with severe hypertension (P = 0.","We conducted an AI-assisted structured evidence synthesis across 55 curated reference papers indexed for Aspirin, extracting effect estimates, confidence intervals, and p-values into an audit-trailed evidence table while preserving the design and directness annotations supplied by the original sources.","The corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 55 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.","Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.","The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","Contextual Adjacent Evidence: n=23; claims=984; mixed signal in 15/23 sources | directness: 14 indirect; 9 review; main limitation: no direct clinical anchor."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\n\"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nAn Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nCan Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAssociation of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\n\"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAspirin Use and Survival Among Patients With Breast Cancer: A Systematic Review and Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nTiming of Aspirin Use Among Patients With Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nAspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\n\"Aspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with use\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nUS population qualifying for aspirin use for primary prevention of cardiovascular disease,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nImpact of aspirin use on clinical outcomes in patients with vasospastic angina: a systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nAspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta‐analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nAspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nMedication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nAssociation between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\n\"Low‐dose aspirin use and colorectal cancer survival in 32,195 patients—A national cohort study\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nEffect of aspirin use on survival benefits of breast cancer patients,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAspirin Use on Incident Dementia and Mild Cognitive Decline: A Systematic Review and Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nEfficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAspirin use for primary prevention among US adults with and without elevated Lipoprotein(a),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nDaily low dose aspirin halves incident type 2 diabetes in elderly subjects with prediabetes: a five-year longitudinal cohort study in a real-word population,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAspirin use is associated with attenuated risk of severe acute kidney injury in septic patients: a dual-center retrospective analysis from MIMIC-IV and eICU cohorts,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAnalysis of prenatal medication use and placental epigenetic gestational age in extremely low gestational age newborns (ELGANs) highlight relationships to aspirin use during pregnancy,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAspirin might reduce the incidence of breast cancer,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAssociation Between Aspirin Usage and Age-Related Macular Degeneration: An Updated Systematic Review and Meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nAspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nAssociations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nEffect of aspirin use on conversion risk from mild cognitive impairment to Alzheimer’s disease,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAssociation of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\n\"Inappropriate Use of Aspirin in Real-Life Cardiology Practice: Results from the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) Study\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nRegular aspirin use among a sample of American Indians/Alaskan Natives in the Upper Midwest region of the United States,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nEffect of pre-ICU aspirin use on neuroinflammation and outcomes in patients with sepsis-associated encephalopathy,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nPromoting Aspirin Use for Cardiovascular Disease Prevention Among an Adult Internet-Using Population: A Pilot Study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nBenefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nAssociation of a Community Population and Clinic Education Intervention Program With Guideline-Based Aspirin Use for Primary Prevention of Cardiovascular Disease,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAssociation Between Prior Aspirin Use and Acute Respiratory Distress Syndrome Incidence in At-Risk Patients: A Systematic Review and Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nContinuous aspirin treatment improves cardiovascular events and all-cause mortality in hemodialysis patients with peripheral artery disease,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nImpact of prior aspirin use on left ventricular function in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: An echocardiographic evaluation,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nDoes prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta‐analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nThe associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nSafety of Continuing Aspirin Use in Cervical Laminoplasty: A Propensity Score-Matched Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAspirin improves short and long term survival outcomes of patients with sepsis associated encephalopathy,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAssociations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nInfluence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\n\"Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nAssociation of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\n\"Shared decision making and patient reported outcomes among adults with atherosclerotic cardiovascular disease, medical expenditure panel survey 2006–2015\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nLow-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort studies.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\n\"Inflammation, Frailty, and Aspirin Use in the Physicians' Health Study: A Pilot Study.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review\r\nAspirin use and pancreatic cancer risk,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nAspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\nDesign and rationale for the ASSOS study: Appropriateness of aspirin use in medical outpatients a multicenter and observational study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,protocol\r\nReduction of intracerebral hemorrhage in hemodialysis patients after reducing aspirin use: A quality-assurance observational study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"145fcccc-2360-4120-8674-34dd3e97ade7","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","doi":"10.1186/s12885-020-07117-4","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"An Evaluation of Aspirin Treatment Preferences of Physicians in Hypertensive Patients in Terms of Current Guidelines: A Subgroup Analysis of the ASSOS Trial in Turkey","doi":"10.5152/AnatolJCardiol.2021.541","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment","doi":"10.3389/fonc.2021.633462","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19","doi":"10.1001/jamanetworkopen.2022.3890","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival","doi":"10.1038/s41523-025-00775-2","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Aspirin Use and Survival Among Patients With Breast Cancer: A Systematic Review and Meta-Analysis","doi":"10.1093/oncolo/oyad186","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Timing of Aspirin Use Among Patients With Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis","doi":"10.1093/jncics/pkab067","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials","doi":"10.3389/fonc.2021.690219","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Aspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with use","doi":"10.1016/j.ajpc.2021.100256","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"US population qualifying for aspirin use for primary prevention of cardiovascular disease","doi":"10.1016/j.ajpc.2024.100669","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Impact of aspirin use on clinical outcomes in patients with vasospastic angina: a systematic review and meta-analysis","doi":"10.1136/bmjopen-2021-048719","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta‐analysis","doi":"10.1002/hep4.1640","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis","doi":"10.3389/fonc.2020.575831","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis","doi":"10.1007/s10552-021-01472-8","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis","doi":"10.1111/jch.14091","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Low‐dose aspirin use and colorectal cancer survival in 32,195 patients—A national cohort study","doi":"10.1002/cam4.4859","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Effect of aspirin use on survival benefits of breast cancer patients","doi":"10.1097/MD.0000000000026870","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Aspirin Use on Incident Dementia and Mild Cognitive Decline: A Systematic Review and Meta-Analysis","doi":"10.3389/fnagi.2020.578071","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Efficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke","doi":"10.12998/wjcc.v11.i32.7814","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)","doi":"10.1016/j.ajpc.2024.100674","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Aspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies","doi":"10.3389/fmed.2020.569759","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Daily low dose aspirin halves incident type 2 diabetes in elderly subjects with prediabetes: a five-year longitudinal cohort study in a real-word population","doi":"10.1186/s12933-025-02802-9","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Aspirin use is associated with attenuated risk of severe acute kidney injury in septic patients: a dual-center retrospective analysis from MIMIC-IV and eICU cohorts","doi":"10.1080/0886022X.2025.2568650","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Analysis of prenatal medication use and placental epigenetic gestational age in extremely low gestational age newborns (ELGANs) highlight relationships to aspirin use during pregnancy","doi":"10.1186/s13148-025-01988-9","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Aspirin might reduce the incidence of breast cancer","doi":"10.1097/MD.0000000000021917","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Association Between Aspirin Usage and Age-Related Macular Degeneration: An Updated Systematic Review and Meta-analysis","doi":"10.3389/fphar.2022.824745","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis","doi":"10.1016/j.ahjo.2022.100191","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis","doi":"10.3389/fphar.2022.989903","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Effect of aspirin use on conversion risk from mild cognitive impairment to Alzheimer’s disease","doi":"10.3389/fnagi.2025.1603892","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study","doi":"10.1080/07853890.2025.2573146","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Inappropriate Use of Aspirin in Real-Life Cardiology Practice: Results from the Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) Study","doi":"10.5152/balkanmedj.2021.21143","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Regular aspirin use among a sample of American Indians/Alaskan Natives in the Upper Midwest region of the United States","doi":"10.1016/j.pmedr.2023.102571","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Effect of pre-ICU aspirin use on neuroinflammation and outcomes in patients with sepsis-associated encephalopathy","doi":"10.3389/fneur.2026.1708039","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Promoting Aspirin Use for Cardiovascular Disease Prevention Among an Adult Internet-Using Population: A Pilot Study","doi":"10.3389/fpubh.2021.500296","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis","doi":"10.3389/fendo.2021.741374","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Association of a Community Population and Clinic Education Intervention Program With Guideline-Based Aspirin Use for Primary Prevention of Cardiovascular Disease","doi":"10.1001/jamanetworkopen.2022.11107","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Association Between Prior Aspirin Use and Acute Respiratory Distress Syndrome Incidence in At-Risk Patients: A Systematic Review and Meta-Analysis","doi":"10.3389/fphar.2020.00738","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Continuous aspirin treatment improves cardiovascular events and all-cause mortality in hemodialysis patients with peripheral artery disease","doi":"10.1080/0886022X.2024.2380754","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Impact of prior aspirin use on left ventricular function in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: An echocardiographic evaluation","doi":"10.34172/jcvtr.33184","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta‐analysis","doi":"10.1111/ene.15433","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis","doi":"10.1186/s40246-024-00699-1","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Safety of Continuing Aspirin Use in Cervical Laminoplasty: A Propensity Score-Matched Analysis","doi":"10.22603/ssrr.2022-0163","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Aspirin improves short and long term survival outcomes of patients with sepsis associated encephalopathy","doi":"10.1038/s41598-025-08075-2","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults.","doi":"10.1093/geroni/igab046.2339","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019.","doi":"10.1016/j.clbc.2021.02.005","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis.","doi":"10.1016/j.clinre.2020.09.006","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019.","doi":"10.1213/ane.0000000000005292","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes","doi":"10.1101/2022.08.03.22278392","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Shared decision making and patient reported outcomes among adults with atherosclerotic cardiovascular disease, medical expenditure panel survey 2006–2015","doi":"10.1016/j.ajpc.2021.100281","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Low-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort studies.","doi":"10.1093/pubmed/fdz114","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Inflammation, Frailty, and Aspirin Use in the Physicians' Health Study: A Pilot Study.","doi":"10.14283/jfa.2024.37","risk_of_bias":"not appraised in public sidecar","directness":"review"},{"study":"Aspirin use and pancreatic cancer risk","doi":"10.1097/MD.0000000000018033","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials","doi":"10.1186/s12933-019-0875-4","risk_of_bias":"not appraised in public sidecar","directness":"indirect"},{"study":"Design and rationale for the ASSOS study: Appropriateness of aspirin use in medical outpatients a multicenter and observational study","doi":"10.14744/AnatolJCardiol.2018.47587","risk_of_bias":"not appraised in public sidecar","directness":"protocol"},{"study":"Reduction of intracerebral hemorrhage in hemodialysis patients after reducing aspirin use: A quality-assurance observational study","doi":"10.1371/journal.pone.0185847","risk_of_bias":"not appraised in public sidecar","directness":"indirect"}]}}]}